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 Glossary: 
 
Caseloading - Managing Jobcentre Plus Personal Adviser time to achieve 
regular contacts between a customer and a specific Adviser. 
 
District Drug Co-ordinator - Introduced in Jobcentre Plus in England from 
April 2009 along with the RDSLs (see description below). DDCs were the 
local partnership managers responsible for: developing and strengthening 
relationships with external agencies in the drugs field; raising awareness 
amongst them of JCP’s programmes and services; and ensuring that JCP 
staff have the skills and support necessary to identify, refer and work 
effectively with substance misusing customers. The funding for the DDC role 
came to an end in March 2011, however the key functions of this role are still 
being carried out. Jobcentre Plus Districts now have the flexibility to decide 
how best to deliver them in light of their local priorities and resource. 
 
Drug (and Alcohol) Action Teams - Multi-agency partnerships, responsible 
for the local implementation of the drug (and, where applicable, alcohol) 
strategy. 
 
Drug Champion – Jobcentre Plus local office front-line staff (for example 
Personal Advisers) who have agreed to take on responsibility for supporting 
drug strategy activities in their office in addition to their other duties. Activities 
include raising awareness of the voluntary referral process amongst 
colleagues, supporting them in identifying and working effectively with 
substance misusing customers, and supporting the work of their DDC. There 
should be at least one Drug Champion in each JCP office. 
 
Labour market system - The computer system used by Jobcentre Plus to 
record customer details. 
Personal Advisers - Members of front-line staff in Jobcentre Plus responsible 
for holding interviews with customers, deciding on the best way forward for 
them and working with them to move them into or closer to the labour market. 
Regional Drug Strategic Lead – Introduced in Jobcentre Plus in England 
from April 2009 along with the DDCs, RDSLs were responsible for the drug 
agenda within JCP on a regional level, and oversaw the work of the DDCs. 
The funding for the RDSL role came to an end in March 2011. 
 
PDU markers – Markers contained on individual customer records in the LMS 
system which Personal Advisers can use to record disclosures by customers 
of heroin and/or crack cocaine use, and whether or not the customer is in 
treatment.  
 
National Treatment Agency for Substance Misuse – The National Health 
Service special health authority established to improve the availability, 
capacity and effectiveness of drug treatment in England.  
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 Outreach – Services provided by Jobcentre Plus staff in locations other than 
the Jobcentre. In this report, JCP outreach refers to sessions conducted by a 
Personal Adviser in a drug treatment provider’s premises.  
 
Problem Drug User – An individual who uses heroin (or other opiates) and/or 
crack cocaine. 
 
Voluntary referrals – From April 2009, Jobcentre Plus customers in England 
who were in receipt of either JSA or ESA and disclosed a problem with heroin 
and/or crack cocaine but were not in treatment for this problem were eligible 
for a voluntary referral to a discussion of treatment options with a local 
treatment provider. Voluntary referrals have now been opened up to JCP 
customers receiving any benefit who have a problem with any substance, 
where the use of that substance represents a barrier to work. 
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 Executive Summary 
 
Background  
The Department for Work and Pensions’ (DWP) is committed to helping 
individuals tackle their substance misuse problems. As part of this 
commitment Jobcentre Plus (JCP) introduced a system of voluntary referrals 
for customers to a discussion with a treatment provider in April 20091. It was 
hoped that these referrals would help to significantly increase the number of 
people being referred to treatment providers, and subsequently engaging in 
treatment.  
 
Although this initiative has seen some success, with 2,500 referrals made by 
August 2010, stakeholders were concerned that only a small proportion of 
those customers who would benefit from this opportunity had taken it up2. The 
Intensive Activity (IA) trial was developed in response to this, to explore 
whether a model of closer working between JCP and treatment providers 
could increase the number of disclosures of substance misuse by customers 
to JCP and the number of voluntary referrals; and improve the service offered 
by JCP to substance misusing customers.  
 
Three Jobcentres were selected for the trial on the basis of their having a high 
estimated number of customers who are substance misusers and not in 
treatment, but a relatively low number of achieved referrals. The trial, which 
took place between May and July 2010, lasted 8 weeks in two of the 
Jobcentres and four weeks in a third. It involved a treatment provider 
presence in the Jobcentre for multiple sessions per week, as well as a variety 
of other supporting activities.  
 
This report contains the findings from the evaluation of the IA trial. It explores:  
 whether IA can produce an increase in the numbers of disclosures and 
referrals;  
 what the main positive and negative elements of the trial were;  
 best practice when implementing IA; and 
 best practice when working with substance misusing customers more 
generally.  
 
The evaluation consists of qualitative evidence derived from focus groups and 
interviews with key stakeholders in JCP, the treatment providers and the local 
D(A)ATs, as well as front-line JCP and treatment provider staff involved in the 
initiative. Fieldwork was conducted between June and September 2010. 
Management Information on the number of disclosures of substance misuse3 
                                            
1 Voluntary referrals were introduced to Jobcentres in England only. 
2 The Department estimates that there are around 30,000 users of heroin and/or crack 
cocaine in England who are in receipt of Jobseeker’s Allowance (JSA) or Employment and 
Support Allowance (ESA) but are not in treatment. The voluntary referral system was 
originally only open to users of heroin and/or crack cocaine on JSA or ESA, but during the 
trial was opened up to users of any substance on any benefit.  
3 This is measured using the proxy of the number of problem drug use (PDU) markers that 
were set on the Labour Market System (LMS), which is the computer system used by JCP to 
record customer details. 
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 and the number of voluntary referrals recorded by the three Jobcentres 
before, during and after the trial was also collected. 
 
Qualitative Findings 
What worked well 
 Stakeholders broadly felt that the model of closer working between 
JCP and treatment providers trialled was successful and central to any 
increase in referrals that occurred during the trial period. JCP front-line 
staff said they were more comfortable raising the issue of substance 
misuse with customers knowing that the provider was on hand to take 
over any difficult discussions. Stakeholders from both JCP and the 
treatment provider reported having a better understanding of the 
support offered by the other party and, as a result, were better placed 
to deliver more informed advice. 
  
 Outreach by JCP staff in the treatment provider premises was felt to be 
a good way of engaging with hard-to-reach customers in an 
environment in which they felt comfortable and unafraid of stigma. 
 
 The trial was successful in raising awareness within Jobcentres of the 
importance of staff broaching the issue of substance misuse with 
customers, and in supporting them to do so. The contribution of the 
District Drug Co-ordinators4 and Drug Champion/s5, training for staff on 
how to ask customers about substance misuse and deal with 
disclosure, and enabling JCP staff to ‘case conference’6 within their 
teams were thought to be particularly valuable.  
 
 Caseloading substance misusing customers to the Drug Champion 
was seen as positive both for the customers, who benefited from 
greater continuity and more intensive support, and for those JCP staff 
who said they were not comfortable discussing substance misuse with 
customers. 
 
What worked less well / problems encountered 
 Due to concerns around JCP staff safety, JCP Health and Safety risk 
assessments required before the treatment provider sessions in the 
                                            
4 District Drug Co-ordinators were the local partnership managers in JCP responsible for 
developing and strengthening relationships with external agencies in the drugs field; raising 
awareness amongst them of JCP’s programmes and services; and ensuring that JCP staff 
have the skills and support necessary to identify, refer and work effectively with substance 
misusing customers. The funding for the DDC role came to an end in March 2011, however 
the key functions of this role are still being carried out. Jobcentre Plus Districts now have the 
flexibility to decide how best to deliver them in light of their local priorities and resource. 
5 Drug Champions are JCP local office front-line staff (including Advisers) who have agreed to 
take on responsibility for supporting drug strategy activities in their office in addition to their 
other duties. Activities include raising awareness of the voluntary referral process amongst 
colleagues, supporting them in identifying and working effectively with substance misusing 
customers, and supporting the work of their District Drug Co-ordinator. 
6 Case conferencing involves JCP front-line staff discussing with their team how best to work 
with individual customers who have disclosed, or who they suspect have, substance misuse 
issues.  
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 Jobcentres resulted in significant restrictions being placed on the 
activities treatment providers could carry out whilst in two of the trial 
Jobcentres7. For example, treatment providers were not allowed to 
approach customers or advertise their presence in the office, and 
Jobcentre Plus front-line staff were not permitted to visit the treatment 
provider’s premises. Stakeholders in these two offices reported that 
this was frustrating and damaging to the trial.  
 
 Operational pressures also represented a barrier to the success of the 
trial. Advisers were concerned about raising the issue of substance 
misuse with customers in case a disclosure, and lengthy discussion 
with them around it, prevented them from dealing with the other issues 
they are required to cover during their time-limited appointments. 
Additionally many were not released to attend training sessions on 
working with substance misusing customers due to operational 
pressures, despite having a skills gap in this area.  
 
 Productivity targets around starts to training and employment were a 
significant issue for the Drug Champions who were responsible for 
conducting outreach sessions in the treatment provider premises and 
caseloading substance misusing customers. They found it difficult to 
achieve their targets whilst also devoting increased time to working 
with substance misusing customers, who require more intensive 
support than most customers to achieve the same outcomes.  
 
 Having effective communications within the Jobcentre was an 
additional barrier in two of the offices. Due to the lack of all-staff 
meetings, stakeholders reported difficulty in finding the right platform 
through which to raise awareness of the trial and the treatment 
provider’s presence amongst staff. 
 
Overall success and sustainability over the longer term 
Views about the overall success of the IA trial were mixed. There was 
widespread agreement that the trial period was relatively short and any 
success represented only the start of what could be achieved over the longer 
term. Stakeholders in two of the trial offices felt that the success of the trial 
had not been reflected in the limited increase in disclosures and referrals.  
 
However, on the whole stakeholders were positive about the overall impact of 
the trial, citing improvements in:  
 the confidence, motivation and skills of JCP staff in working with 
substance misusing customers;  
 the profile of the substance misuse agenda within JCP;  
 working relationships between the JCP office and the treatment sector; 
and  
                                            
7 These restrictions are not reflective of Jobcentre Plus (or DWP) Health and Safety Policy, 
which allows for such activities to take place provided that suitable risk assessment 
processes have been followed and any necessary control measures or risk mitigations put in 
place, but instead were a result of decisions taken at the local Jobcentre Plus office level. 
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  the standard of service provided by JCP to substance misusing 
customers.  
 
The exception to this view was held by some stakeholders in one of the 
offices who felt that the trial had not been successful, largely as a result of the 
outcome of the Health and Safety risk assessment. 
 
Following the trial period, maintaining IA over the longer term was thought to 
be realistic from the point of view of the JCP staff resource required, in spite 
of operational pressures and targets. The treatment providers reported having 
to reduce the amount of time they spent in the Jobcentre due to resource 
constraints, and an insufficient increase in the number of referrals during the 
trial to justify sustaining the activity on that scale. However, all three intended 
to continue working more closely with JCP, and two intended to maintain one 
session a week in the Jobcentre.  
 
Quantitative Findings 
Table 1 contains details of the number of customers voluntarily referred to a 
discussion with a treatment provider achieved by each Jobcentre before, 
during and after the trial period. They should be understood in the context of 
the qualitative findings. 
 
Table 1: Referrals in JCP A, B and C by time period in which they were    
               made 
 
 Referrals made by trial JCP office 
Time Period JCP A1 JCP B JCP C 
Before trial (6 
months prior to 
trial start) 13 1 12
During trial (JCP 
A & B - 8 weeks; 
JCP C – 4 
weeks) 
6 (+ 2 self-
referrals)2 3 21
Post trial (3 
months after trial) 2 4 55
1Only PDUs were referred before the trial, but during and following the trial misusers 
of any substance (including alcohol) were referred. Also note that closer working was 
already taking place in JCP A prior to the trial period, although in a less intensive 
form. 
2 ‘Self-referrals’ are customers who visited the treatment provider to discuss treatment 
options after finding out about them through the Jobcentre, but who were not officially 
referred by JCP. 
 
Conclusion and Recommendations 
 The impact of the trial on disclosures and referrals to a treatment 
provider was variable, but increases were seen in all three Jobcentres. 
However, even in Jobcentre C which saw the largest increase, the 
number of referrals was still substantially smaller than the estimate 
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 which JCP hoped could be achieved8, indicating that these estimates 
may need to be revised downwards. 
 
 Given the limited increase in referrals achieved during the trial and its 
resource intensive nature, it is unlikely that in the current climate many 
JCP offices will be able to justify adopting intensive activity on this 
scale with a view to increasing the volumes of such referrals. 
 
 Lessons for best practice for those JCPs who do wish to adopt such a 
model include: involving the treatment provider early on in the design of 
the activity; securing buy-in from JCP senior management; developing 
standard guidance for conducting Health and Safety risk assessments 
in advance of the activity; and ensuring good communications with JCP 
staff around the trial. 
 
 Importantly, the evaluation also identified various lessons for best 
practice within JCP around supporting substance misusing customers 
more generally. These include: having effective and dedicated Drug 
Champions within each Jobcentre; the importance of close 
partnerships between the treatment sector and JCP; ensuring JCP staff 
receive training on raising the issue of substance misuse and dealing 
with disclosures; JCP outreach at treatment provider premises; 
caseloading substance misusing customers to a Drug Champion or 
other skilled Adviser; and tailoring productivity targets for any dedicated 
advisers working with this group. 
                                            
8 JCPs estimates were as follows: JCP A – 143 customers who are heroin and/or crack 
cocaine users, in receipt of JSA or ESA and not in treatment; JCP B – 113 customers who are 
heroin and/or crack cocaine users, in receipt of JSA or ESA and not in treatment; JCP C – 92 
customers who are heroin and/or crack cocaine users, in receipt of JSA or ESA and not in 
treatment. Estimates of the number of customers addicted to any substance (including 
alcohol) and on any benefit (but not in treatment) would be substantially higher. These figures 
were derived from published DWP estimates (Hay, G., and Bauld, L. (2008) Population 
estimates of Problematic Drug Users in England who access DWP benefits. DWP Working 
Paper No. 46) and treatment take-up information.  
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 1. Background 
 
The Coalition Government has stated that it is committed to tackling drug and 
alcohol addiction, which it views as one of the most damaging root causes of 
poverty. The Government believes in an approach to tackling addiction that is 
firmly rooted in the concept of recovery and reintegration; a process through 
which an individual is enabled to overcome the symptoms and causes of their 
dependency, and become an active and contributing member of society. The 
Department for Work and Pensions (DWP) have joint responsibility for the 
‘recovery and reintegration’ strand of the 2010 Drug Strategy ‘Reducing 
demand, restricting supply, building recovery: supporting people to live a drug-
free life’9. This strand is concerned with enabling the development of a system 
whereby treatment, employment, education and skills programmes, family 
support, probation and wider health services around treatment are delivered 
in a holistic, person-centred fashion to support sustained recovery for 
substance misusers. 
 
As part of DWP’s commitment to helping individuals tackle their substance 
misuse problems, a system of voluntary referrals to a discussion of treatment 
options with a treatment provider was introduced into Jobcentre Plus (JCP) in 
April 2009. The voluntary referral was initially designed to be offered to JCP 
customers in England who are in receipt of Jobseekers Allowance (JSA) or 
Employment and Support Allowance (ESA) and are a Problem Drug User 
(PDU), meaning that they use heroin and/or crack cocaine. If a customer 
agrees that they would benefit from a discussion with a treatment provider, an 
appointment with a local treatment provider to discuss available treatment 
options is then arranged for them.  
 
District Drug Coordinators (DDCs), who were also introduced into JCP in April 
2009, were the local partnership managers responsible for supporting the 
drug strategy on the ground. This included raising awareness of the voluntary 
referral process amongst JCP staff, arranging training for staff on substance 
misuse issues and the process of making a referral, and ensuring that the 
process is working successfully10. From April 2009 to the end of August 2010, 
in England 10,300 customers were identified as PDUs and had the relevant 
marker set on their Labour Market System (LMS)11 records. Nearly 8,000 of 
these customers were in treatment at the time the marker was set and 2,400 
were not in treatment. In the same time period a total of 2,500 referrals were 
made, which resulted in 861 recorded discussions with a treatment advisor12. 
Given that DWP estimates put the number of PDUs in England accessing JSA 
                                            
9 Home Office (2010) 
10 Funding for the DDC role came to an end in March 2011. The key functions of this role are 
still being carried out, but Jobcentre Plus Districts have the flexibility to decide how best to 
deliver them in light of their local priorities and resource. In some Districts these functions are 
being encompassed into a new role which has a wider remit to consider all excluded and 
disadvantaged groups. 
11 LMS is the computer system used by JCP to record customer details. 
12 Due to restrictions around data sharing between treatment providers and JCP without the 
customers’ consent, the actual number of discussions that have taken place are not known 
but are likely to be higher than the recorded number. 
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 or ESA and not in treatment at 30,00013, the number of referrals made by 
August 2010 stood at just over 8% of the total potential number of PDU 
referrals which we estimate JCP could make14.  
 
Concern about the low number of identifications and referrals being recorded 
led to the development of the Intensive Activity (IA) trial. The purpose of the 
trial was to explore whether a model of closer working between JCP and 
substance misuse treatment providers could potentially increase the numbers 
of disclosures of drug and alcohol misuse by customers to JCP and of 
voluntary referrals being made to a treatment provider; and improve the 
service offered by JCP for substance misusing customers15. The decision was 
taken to extend voluntary referral offer in the trial areas to customers on any 
benefit and misusing any substance, including illegal drugs, prescription 
drugs, and alcohol. This decision reflected the Coalition Government’s focus 
on helping customers for whom the abuse of any substance is a barrier to 
employment to overcome their problems and move back into work. 
 
Three Jobcentres were selected for the trial on the basis of their having a high 
estimated number of customers who are PDUs and not in treatment (and are 
therefore eligible for referral to a treatment provider), but a relatively low 
number of achieved referrals. The trial took place between May and July 
2010, lasted 8 weeks in two of the Jobcentres and four weeks in the third. It 
involved a treatment provider presence in the Jobcentre for multiple sessions 
per week, as well as a variety of other supporting activities. Further 
information about these three Jobcentres and the activities that took place in 
them during the IA trial period can be found in Chapter 3. 
                                            
13 This estimate is based on those contained in the following DWP report: Hay, G., and Bauld, 
L. (2008) Population estimates of Problematic Drug Users in England who access DWP 
benefits. DWP Working Paper No. 46. 
14 This calculation assumes that individuals who are already in treatment would not be 
referred by JCP staff, although there may be situations in which a referral would still be 
judged to be valuable.  
15 Independently-conducted research commissioned by DWP highlighted the negative 
experiences that many substance misusers report in relation to JCP. These included dealing 
with advisers who they felt were not sufficiently responsive to and understanding of their 
circumstances and needs, and who they felt were not supportive enough in helping them to 
resolve problems with their benefits: Bauld, L., Hay, G., McKell, J., and Carroll, C. (2010) 
Problem Drug Users’ experiences of employment and the benefit system. DWP Research 
Report No. 640; Bauld, L., Carroll, C., Hay, G., McKell, J., Novak, C., Silver, K., and 
Templeton, L. (2010) Alcohol misusers’ experiences of employment and the benefit system. 
DWP Research Report No. 718. 
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2. Evaluation Aims and Methodology 
 
2.1 Aims 
 
The key aims of the evaluation were: 
 
 To explore the views of JCP staff and treatment sector professionals 
on the effectiveness, efficiency and sustainability of the key elements 
of the IA trial; 
 
 To assess whether IA has the potential to increase the numbers of 
disclosures of drug and alcohol misuse being made by customers to 
Jobcentre staff and voluntary referrals being made to a treatment 
provider; 
 
 To explore qualitative measures of success including (but not limited 
to) improved working relationships between JCP and treatment 
providers, and increased JCP staff skills in working with substance 
misusing customers; and  
 
 To produce recommendations for good practice when designing and 
implementing an IA initiative, and when working with substance 
misusing customers more generally. 
 
2.2 Methodology 
 
The main element of the evaluation consisted of qualitative research with key 
stakeholders exploring their perceptions of the impact of the trial and its 
success, or lack of it. Limited quantitative data in the form of Management 
Information was also collected to enable comparison of the number of 
referrals and disclosures taking place before, during and after the trial. 
However, this data should be interpreted with caution due to the very small 
number of trial sites involved and the relatively brief duration of the trial. 
These two strands of the evaluation are discussed in more detail below.  
 
The final report was peer reviewed by a DWP Principal Research Officer 
working in a different policy area. 
 
2.2.1 Qualitative Strand 
The main strand of the evaluation utilised qualitative methods to explore in 
depth stakeholders’ perceptions of the impact of the trial, including which 
elements worked well and were successful, which were less successful, what 
issues were encountered during the trial and how any problems were 
overcome, and the feasibility of sustaining IA over the longer term. The 
fieldwork took place between June and September 2010 following the end of 
the official IA trial period in each Jobcentre. A mixture of focus groups (lasting 
between one and a half and two hours) and face-to-face and telephone semi-
structured interviews (lasting between 20 minutes and one hour) was 
employed to elicit views from key stakeholders involved in the trial. These 
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 included staff at various levels from each trial Jobcentre (including those with 
a specific remit around the drug strategy), as well as the treatment provider 
staff who took part in the trial, and representatives from the National 
Treatment Agency for Substance Misuse (NTA), and the local Drug (and 
Alcohol) Action Teams (D(A)ATs) who commission treatment services.  
 
In addition, two focus groups with JCP front-line staff (predominantly Personal 
Advisers) were also conducted in each trial site. Care was taken to ensure 
that a range of Advisers were recruited so that the diversity of opinion was 
captured. This included advisers from different teams, of different levels of 
experience, and with different degrees of involvement in the trial.  
 
Semi-structured topic guides were used during the focus groups and 
interviews to ensure that the key issues were explored with all participants 
(see Appendices A and B). Detailed notes were taken during the course of all 
focus groups and interviews as it was not possible to record the interactions. 
These notes formed the basis of the information which has been analysed 
and reported on in Chapter 4. The information was analysed using thematic 
analysis techniques. 
 
2.2.2 Quantitative Strand 
This element of the research took the form of a before-and-after comparison 
of the number of referrals being made to a treatment provider in each of the 
three Jobcentres, and the number of disclosures of substance misuse being 
made, before, during and after the trial. This latter outcome was measured 
using the proxy of the number of Problem Drug Use markers that were set on 
LMS. This measure is likely to be an undercount of the number of disclosures 
taking place as it only includes those customers who have admitted to using 
heroin or crack cocaine, and only those who have agreed to JCP placing this 
information on their record. However, it is likely to give a broad indication of 
any increase or decrease in the number of disclosures being made.  
 
The before-and-after evaluation design represents a very simple method of 
measuring the impact of an intervention. It does not involve the consideration 
of a counterfactual (in other words, what would have happened if the 
intervention was not introduced) and therefore is subject to a number of 
criticisms. These include the fact that outcomes, in this case the numbers of 
disclosures and referrals recorded, could have increased or decreased during 
the trial period for a reason unrelated to the trial itself. For example, a change 
in patterns of drug use or benefit uptake during the period of the trial could 
have an impact on the numbers of disclosures and referrals taking place. One 
way of deriving a counterfactual, thereby producing a more robust evaluation, 
is to identify Jobcentre sites which are very similar to those involved in the trial 
but are not introducing IA to serve as a comparison. However, as there was 
no robust way of identifying such comparison sites the before-and-after 
design was the only feasible option. 
 
As a result of these limitations, and due to the very small scale of the trial, 
care should be taken not to place too much emphasis on the quantitative 
evaluation findings. Additionally, for the same reasons, robust cost-benefit 
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 analysis that could be extrapolated to other Jobcentres could not be 
produced, and hence information of this nature is not provided here.  
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 3. Intensive Activity Trial 
 
This section provides a brief description of the Jobcentres selected for the 
trial, the treatment providers who took part in each area, and the activities that 
were undertaken as part of the IA. The exact nature and extent of the IA 
initiative was left to the trial Jobcentres and treatment providers to develop 
and agree in each area, the only stipulation being that it should involve closer 
working between JCP and treatment providers with the treatment provider 
having a greater presence in the Jobcentre. The three sites developed 
broadly similar models with variations resulting from differing local needs and 
resource. 
 
As mentioned above, the JCP offices involved in the trial were selected on the 
basis of their having a high estimated number of customers who are PDUs 
and not in treatment (and therefore are eligible for referral to a treatment 
provider), but a relatively low number of achieved referrals. 
 
3.1 JCP A 
 
3.1.1 Jobcentre description 
Jobcentre A is situated in one of the most deprived areas of a large city, with 
high levels of unemployment. The office has a large customer base including 
around 5,000 customers claiming JSA and 12,000 claiming ESA and IB. JCP 
A has 140 staff including 5 Adviser Team Managers (ATMs) and 1 Jobcentre 
Manager (JCM). 
 
The area has a large number of residents with English as a second language, 
a high prevalence of crack cocaine users, and contains a higher than average 
proportion of people with no qualifications. The main sources of employment 
are the local authority and the retail sector. 
 
DWP estimates suggest that the office has a total of 143 potential referrals16. 
 
3.1.2 Treatment provider description 
The treatment provider who participated in JCP A’s IA trial provides a service 
where crack cocaine and poly-drug users can receive information and advice 
to help them deal with issues relating to their substance misuse. They run a 
drop-in centre offering individual and group counselling, one-to-one key 
working sessions, a needle exchange, complimentary therapies, computer 
access, and hot meals, amongst other services. 
 
3.1.3 IA Trial description 
The IA trial in JCP A ran for a period of eight weeks, starting on the 24th May 
and ending on the 23rd July 2010. A scoping meeting involving Jobcentre Plus 
                                            
16 This figure was derived from published DWP estimates (Hay, G., and Bauld, L. (2008) 
Population estimates of Problematic Drug Users in England who access DWP benefits. DWP 
Working Paper No. 46) and treatment take-up information, and relates to the number of 
individuals in England who are dependent on heroin and/or crack cocaine, in receipt of JSA or 
ESA and not in treatment. 
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 managers and team leaders, the District Drug Co-ordinator (DDC) and 
Regional Drug Strategic Lead, as well as NTA and DWP representatives, was 
held prior to the start of the IA to agree the programme of activities that would 
take place. It is important to note that JCP A already had a close working 
relationship with their local treatment provider, and that the provider had been 
providing a presence once a week in the Jobcentre for approximately 8 
months prior to the start of the trial – although only when the DDC was 
present. During these sessions the provider spoke to customers about their 
services, and had appointments with customers who had been referred to 
them for a discussion about treatment options. Prior to the trial only PDUs in 
receipt of JSA or ESA were referred to the treatment provider, and at the 
initial meeting stakeholders decided to keep the focus on this group during the 
trial. However, soon after this and before the start of the trial the decision was 
taken to extend the referrals to include misusers of other drugs and alcohol 
who were in receipt of other benefits. For this Jobcentre, unlike the two 
others, the IA represented an extension of a closer working initiative that was 
already in place. As a result there was no need for a new health and safety 
risk assessment for this element of the trial, as having the treatment providers 
attend the office and interact with customers was already covered by the 
existing risk assessment. 
 
The first week of the trial consisted of a familiarisation phase, during which 
two Advisers from each of the customer stages (10 Advisers in total) attended 
the treatment provider premises during an open day. During this day they 
found out more about the services the provider offered, and about the nature 
of substance misuse and treatment. The Advisers then fed this back to the 
rest of their teams. The treatment provider also delivered a workshop along 
with a local provider of alcohol treatment services to 12 JCP staff to raise 
awareness of drug and alcohol issues. This workshop covered signs of drug 
or alcohol abuse to look out for, how to broach the issue of substance misuse 
with customers in a sensitive way, and how to manage conflict with and 
emotional breakdown from customers in relation to this issue. The workshop 
involved presentations, discussions and role plays. Those treatment provider 
staff who had not already been attending the Jobcentre familiarised 
themselves with the office during this week.  
 
Two review meetings involving key stakeholders took place during the course 
of the trial to monitor progress against its key aims and to make revisions or 
improvements to the operating model if necessary. These took place at the 
end of the first week (during which an action plan for the rest of the trial was 
drawn up) and at the end of week 5. 
 
During weeks 2 to 8 two staff from the treatment provider were involved in 
attending JCP A three times per week, with one member of staff attending 
during each session. The sessions were held on different days each week to 
maximise the number of customers who had the opportunity to speak to the 
treatment provider. During these sessions the treatment provider floor-walked, 
unaccompanied by a member of JCP staff, and approached customers to 
raise awareness of the treatment services on offer. They also sat in on and 
observed customer interviews, provided the agreement of the customer was 
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 secured beforehand, to gain a better understanding of what happens during 
them. The treatment provider had a desk in a prominent position in the JCP 
office on which they were able to set up a display of leaflets and literature, 
however they often lacked a private space in which to have discussions with 
customers when referrals were made. The treatment provider was allowed to 
conduct team meetings and take breaks in the staff canteen, and was 
encouraged to approach and engage with staff in all teams, including the 
Fortnightly Job Review (FJR) and Crisis Loan teams. 
 
Another key element of the trial involved a JCP Adviser conducting outreach 
sessions at the treatment provider premises. The Adviser who undertook this 
role was already familiar with the treatment provider as a result of 
volunteering with them in her own time for several months prior to the start of 
the trial. She had also nominated herself for the Drug Champion role within 
JCP A at a similar time, and was very interested in working with substance 
misusing customers. During the IA trial she conducted outreach sessions one 
afternoon a week, for a total of five weeks, on behalf of JCP at the treatment 
provider. The first of these was a scoping session involving a group of service 
users to canvass their views on what they wanted to get out of the sessions, 
and how they would prefer them to be run and structured. Due to 
confidentiality issues she saw customers on a private, one-to-one basis in the 
following four sessions. The treatment provider booked appointments on her 
behalf with customers who wished to see her, then called her to let her know 
who she was scheduled to see and what they wanted to talk about. This 
enabled her to prepare for the appointments by looking up the customers’ 
LMS records before the outreach sessions to get a better picture of their 
history and current situation.  
 
A Health and Safety risk assessment was required before the outreach 
activity could go ahead to ensure that it would not pose any serious risks to 
the Drug Champion. An Adviser from the Lone Parents team who was 
experienced at conducting assessments for outreach at children’s centres 
attended the treatment provider premises, along with the Drug Champion and 
the manager of the treatment provider, to undertake the risk assessment a 
week prior to the start of the outreach sessions. She ensured that all 
appropriate risks relating to the working environment were explored, including 
the risk of substance misusers who aren’t stable in treatment potentially 
displaying aggressive or violent behaviour. Flexibility on the part of the 
treatment provider was necessary to find an alternative room to that originally 
proposed for the outreach sessions which had an easier exit route for the 
Drug Champion should she feel threatened during her appointments. The 
treatment provider also agreed to install a panic alarm in this room for the 
Drug Champion to use if necessary. Following these adjustments the Adviser 
gave approval for the outreach to go ahead. 
 
Additional supporting actions that were undertaken as part of the IA trial 
included promoting the use of the locally produced ‘Are you missing out’ form 
(see Appendix C) to help staff raise the issue of drug and alcohol use in the 
context of other barriers to work, and without having to ask this question out 
loud. Case-conferencing within teams took place, in which Advisers had the 
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 opportunity to discuss with colleagues and their team leader (ASM) how best 
to handle any cases where they believed or knew a customer to be a 
substance misuser. Guidance on Adviser flexibility around sanctions for non-
compliance with benefit conditionality (eg. in the case of JSA, fortnightly 
signing and proof of job search activity) when drug or alcohol misuse was 
involved was re-issued.  
 
Coinciding with the start of the IA trial was a four-week exercise to increase 
the number of Disadvantage Markers being recorded on LMS. This involved 
Advisers being encouraged to ask all new Stage 3 New Deal customers 
whether any of the disadvantages (including ex-offender, homeless, refugee 
and drug or alcohol misuser) applied to them, and recording them on LMS if 
they did (provided the customer consented). Advisers were instructed to 
encourage customers who disclosed drug or alcohol misuse to take up the 
offer of a referral to a treatment provider. Additionally, the exercise involved a 
one-off drive to ask all stock Stage 3 New Deal customers about whether any 
of the disadvantages applied to them, and similarly to encourage those 
customers who did disclose substance misuse to take up the voluntary 
referral opportunity.  
 
Following the end of the trial the treatment provider reduced their attendance 
at the JCP back down to one session a week as a result of resource 
constraints on their part. The JCP outreach at the treatment provider premises 
stopped during the summer holiday period as the Drug Champion conducting 
it only worked during term time, and it wasn’t deemed feasible to train up 
another Adviser to cover this role while she was away. However, it was 
anticipated that the activity would resume when she returned in the autumn, 
and discussions were due to take place then about the possibility of the 
Adviser conducting outreach at another local treatment provider who had 
expressed an interest in becoming a JCP outreach site. 
 
3.2 JCP B 
 
3.2.1 Jobcentre description 
JCP B is a purpose built Jobcentre Plus office and was the pathfinder office 
for the District. Its current register contains approximately 4,000 customers. 
The Jobcentre employs around 100 staff, including 4 ATMS and one JCM.  
 
It is situated in an urban area close to an area of high deprivation, with a high 
rate of teenage pregnancy and substance misuse. There is very little 
infrastructure in the local area at the moment to provide employment. JCP B 
was selected for the trial on the recommendation of the DAAT Joint 
Commissioning Manager due to the high prevalence of injecting heroin users 
in the area. 
 
DWP estimates suggest that the office has a total of 113 potential referrals17. 
                                            
17 This figure was derived from published DWP estimates (Hay, G., and Bauld, L. (2008) 
Population estimates of Problematic Drug Users in England who access DWP benefits. DWP 
Working Paper No. 46) and treatment take-up information, and relates to the number of 
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3.2.2 Treatment provider description 
The treatment provider who took part in the IA trial at JCP B offers support, 
advice and treatment for individuals misusing any drugs, including prescription 
drugs. They do not currently conduct any formal outreach in any other 
settings, however they are willing to be flexible with regard to visiting service 
users in their preferred location. Alongside treatment and support they also 
offer harm reduction services, for example a needle exchange, and 
vaccinations against Hepatitis B. 
 
3.2.3 IA trial description 
The IA trial in JCP B ran for a period of eight weeks, from 10th May to 2nd July 
2010. As with JCP A, a scoping meeting, in this case chaired by the DERM 
and involving Jobcentre Plus managers and team leaders, the DDC, Drug 
Champion and a JCP Work Psychologist, as well as the DAAT Joint 
Commissioning Manager, was held prior to the start of the trial to agree the 
programme of activities that would take place. It was agreed that during the IA 
period the treatment provider would attend the Jobcentre for four half-day 
sessions a week. Four treatment provider staff were involved in these 
sessions, with one member of staff attending during each session. The DDC 
spent a significant amount of time in JCP B for the duration of the trial. One 
review meeting involving key stakeholders took place at the end of week 3 to 
monitor progress to make revisions or improvements to the IA operating 
model if necessary. 
 
 
An initial familiarisation period of around a week saw the treatment provider 
sitting in on interviews with customers from various stages, including Crisis 
Loan interviews, and talking to a variety of Advisers and staff at all levels to 
gain experience of how JCP works and what standard customer interviews 
are like. They also attended the team meetings of several (though not all) 
teams, and delivered an up-skilling session for front-line staff. This covered 
how to raise the question of substance misuse with customers, and how to 
deal with disclosures when they are made. In addition the treatment provider 
offered to have one-to-ones or small group sessions with Advisers to discuss 
any outstanding issues they may have. The Drug Champion also attended an 
up-skilling session arranged by the DAAT during the trial. 
 
The DDC and Drug Champion facilitated and supported the treatment 
provider’s engagement with JCP staff, and also helped to raise staff 
awareness of their presence during team and Spotlight meetings, and by 
emailing the dates of their sessions to staff.  
 
A Health and Safety risk assessment, conducted prior to the start of the IA 
trial, restricted the treatment provider’s activities during the first four weeks of 
the trial. The treatment provider was not allowed to reveal their identity to 
customers as a provider of services for substance misusers, unless the 
                                                                                                                             
individuals in England who are dependent on heroin and/or crack cocaine, in receipt of JSA or 
ESA and not in treatment. 
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 customer had specifically requested to have a referral to them. They were 
therefore not allowed to wear their usual name badges or to identify 
themselves to customers whose interviews they were sitting in on. They were 
also not allowed to approach customers or advertise their presence, but 
instead sat in a private room during their sessions in the JCP, ready to see 
customers if they were referred to them during this time. However, due to 
stakeholders’ dissatisfaction at this situation a second risk assessment was 
proposed at the review meeting and then conducted during week 4 of the trial. 
JCP senior managers also took the opportunity to meet with the TU 
representative responsible for carrying out the risk assessment to clarify the 
aims and objectives of the IA trial. A representative from the DAAT attended 
the second assessment in order to provide expert guidance and input.  
 
As a result of this second assessment some of the restrictions that were 
placed on the treatment provider were lifted. For example, after this point they 
were allowed to have a desk near the front of the Jobcentre on which to 
display leaflets, posters and a banner to make customers aware of their 
presence, although they were not allowed to man this desk. They were also 
allowed to wear their badges from this point, however were not permitted to 
approach customers. JCP staff were still not allowed to visit the treatment 
provider’s premises to find out more about the services they offer and 
substance misuse generally, as had been originally planned.  
 
As mentioned above, the treatment provider supplied leaflets containing 
information on drug misuse and treatment for Advisers to display on their 
desks and for customers to take away if they wished. These leaflets contained 
the treatment provider’s contact details and information about their services. 
Their details were also added to a sheet given to Crisis Loan applicants 
containing information about local support services. Additionally the Drug 
Champion provided FRANK18 booklets for the Advisers to display and 
distribute to customers where appropriate. 
 
In addition to the treatment provider presence in the Jobcentre, the use of a 
form similar to the locally produced ‘Are you missing out?’ form (see Appendix 
C) to identify customers’ barriers (including drug and alcohol misuse) was 
encouraged. These were used primarily by the 18-24 teams (both by Advisers 
and Signers) but some other teams adopted the use of them as well.  
 
Following the end of the trial, the treatment provider stopped regularly 
attending JCP B, although they were willing to come into the office for pre-
booked referral appointments as and when necessary. They also offered to 
deliver up-skilling sessions to staff whenever there was felt to be sufficient 
need. The JCP had decided to move from a model of one Drug Champion for 
the whole office to one per team, as in JCP C (see below). Additional planned 
activity, time and resource permitting, included the Disability Employment 
                                            
18 FRANK is the Government’s campaign aimed predominantly at young people to provide 
them with advice and information about drug use and treatment. Launched in 2003, they offer 
a 24-hour confidential telephone helpline, an online chat facility and a service providing 
callers/visitors to their website with details of local counselling and treatment services. 
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 Adviser undertaking an exercise to try and identify any PDUs in their 
caseload. 
 
3.3 JCP C 
 
3.3.1 Jobcentre description 
JCP C is a large office situated in a heavily deprived inner city area. It has a 
JSA claimant count of 5,000, and the longest average duration of claim as 
well as the worst performance on-off flows in the region. The Jobcentre 
employs 100 staff, including 3 ATMs and one JCM.  
 
JCP C serves a very diverse customer group including a large BME 
population, amongst whom English language skills are a big issue. Evidence 
suggests that there is a high prevalence of substance misuse in the area.  
 
DWP estimates suggest that the office has a total of 92 potential referrals19. 
 
3.3.2 Treatment provider description 
The treatment provider engaged with the IA trial in JCP C offers services and 
treatment for people who have problems with any drug (including alcohol), 
although their main remit is to work with users of Class A drugs. They aim to 
be able to support service users at every stage of their recovery. Their 
services include engagement on the streets and in communities; harm 
reduction measures at drop-in centres; structured day programmes; 
residential rehabilitation; supported resettlement; and services within prisons. 
They employ a dedicated outreach worker to engage with substance misusers 
in the community, and it was this member of staff who visited JCP C during 
the IA trial. This individual was also involved in outreach projects at a hostel 
and in various other locations at the time of the trial. In addition to treatment 
services the provider also offers personal development programmes to help 
service users gain skills, confidence, motivation, and employment.  
 
3.3.3 IA trial description 
The IA trial in JCP C lasted for four weeks, starting on 21st June and ending 
on the 19th July 2010, making it half the length of the trial in the other two 
sites. As with the other sites, a scoping meeting involving key stakeholders 
was held prior to start of the trial to develop and agree the programme of 
activities that would be taking place. The key strand of the trial was having a 
local treatment provider attend the JCP, in this case for 2 sessions or 
‘surgeries’ a week lasting around three and a half hours each time. During 
these surgeries the dedicated outreach worker from the treatment provider sat 
in a private room or screened area waiting to see customers as and when 
they were referred. When the treatment provider was not in the Jobcentre, 
customers wanting a referral were asked whether they would prefer to have 
                                            
19 This figure was derived from published DWP estimates (Hay, G., and Bauld, L. (2008) 
Population estimates of Problematic Drug Users in England who access DWP benefits. DWP 
Working Paper No. 46) and treatment take-up information, and relates to the number of 
individuals who are dependent on heroin and/or crack cocaine, in receipt of JSA or ESA and 
not in treatment. 
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 an appointment booked with the treatment provider during their next session 
in the JCP, or have their details passed to the DAAT who would then contact 
the customer to arrange a meeting with a local treatment provider. The DDC 
spent most of their time at JCP C during the trial to support the IA, and was 
always present during the treatment provider surgeries. One review meeting 
involving key stakeholders took place half-way through the trial at the end of 
week 2 to monitor progress and to make revisions or improvements to the 
operating model if necessary. 
 
The treatment provider spent four days during the first week of the trial 
familiarising themselves with JCP C, and spent time sitting with Advisers 
observing interviews at different stages in the customer claim, including Crisis 
Loan interviews. They also spent time with the DDC who talked them through 
the customer journey, and the services and support JCP offers to customers. 
In order to increase staff awareness of the IA trial and the treatment provider’s 
presence in the Jobcentre, the provider attended an early morning Spotlight 
meeting and gave a short presentation about their services and the trial. 
Following this initial session the treatment provider attended as many 
Spotlight sessions and team meetings as possible that were taking place 
during the surgeries. Throughout the course of the trial the treatment provider 
made time to sit and talk to staff in between their interviews to discuss and 
raise awareness of substance misuse issues and treatment, setting markers 
on LMS when customers disclose substance misuse, and to give them advice 
on how to raise the issue of substance misuse with customers.  
 
A ‘whole office’ approach to the trial was adopted, which involved a member 
of front-line staff from each team being appointed a Drug Champion. There 
were five Drug Champions in total. Their role was to promote the drug and 
alcohol misuse agenda and raise awareness of the IA trial throughout the 
office, and within their own team in particular. The DDC conducted a 
workshop with the Champions prior to the start of the trial to give them more 
information about the agenda and explain what their role would entail. All five 
Champions had previously attended drug awareness training arranged by the 
DAAT. One of these Advisers - who had been the Drug Champion for the 
office since referrals were introduced in April 2009 and had attended a 
significant amount of training in working with substance misusing customers - 
was appointed the Lead Drug Champion, and was given the role of 
caseloading customers who were known to have, or suspected of having, 
substance misuse issues. This Adviser had one afternoon a week allocated to 
focusing on these customers, during which she saw them in booked 
appointments, or called them to chase up on progress including, where 
relevant, whether they had attended their referral to the treatment provider. 
During these afternoons the regular restrictions around the length of customer 
interviews was lifted and the Adviser was allowed to see the customers for 
longer periods of time to enable her to have a fuller discussion with them 
about their current situation and any support needs. She also saw them more 
regularly to enable her to monitor their progress more closely. The Lead Drug 
Champion spent her time between appointments sitting with other staff during 
their interviews and offering advice on raising the issue of substance misuse 
with customers. Although it had originally been hoped that the Lead 
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 Champion would also be able to conduct outreach sessions at the treatment 
provider premises, the District felt that they could not support this activity and 
as a result it didn’t go ahead. 
 
As in JCP B, a Health and Safety risk assessment meant that there were 
restrictions on the activities that could take place as part of the IA trial. A 
planned trip for the Drug Champions to the treatment provider premises and 
to a hostel in which the provider conducts outreach work – to give them a 
greater understanding of substance misuse and treatment – could not go 
ahead. Concerns were also expressed during the risk assessment about the 
treatment provider observing interviews; using a desk in the front of the JCP 
rather than sitting in a private room or screened area; and putting leaflets and 
posters up in the office to increase awareness of their presence. However, as 
a result of negotiations prior to the start of the trial the issues were resolved 
and these activities were allowed to go ahead. 
 
The DDC created a number of other activities and materials to support the IA 
and raise awareness of the relevant processes. Advisers were provided with a 
question and answer sheet (Appendix D) to help them respond accurately and 
effectively to customer queries about substance misuse and JCP services for 
misusers, and was encouraged to complete a drugs quiz (Appendix E) to 
increase their knowledge. Additionally, the DDC organised referral marker 
walk-through sessions to inform Advisers about the referral process and 
provided the Advisers with a referral process guide to keep on their desks as 
a memory aid (Appendix F). The DDC also encouraged Advisers to keep 
copies of the locally produced ‘Are you missing out?’ form (Appendix C) on 
their desks for customers to complete. Customers in the Back to Work group 
sessions were also asked to complete these forms.  
 
The DDC also spent time looking through the LMS records of customers with 
forthcoming appointments for signs that they may have substance misuse 
issues, including for example having had a marker set in the past, having 
made frequent applications for Crisis Loans or having frequently been 
sanctioned for non-compliance with their benefit regime. When such cases 
were identified the DDC made the Adviser the customer was due to see 
aware so that they could discuss the issue of substance misuse and voluntary 
referrals, if appropriate, during the appointment.  
 
Following the four-week trial, the treatment provider scaled back their 
presence in the Jobcentre to one morning a week, during which he is able to 
see up to 6 clients in booked appointments. However, the provider aimed to 
be as flexible as possible and come straight down to the JCP to see 
customers as soon as they had been referred, if he was available and in the 
area. He also offered to deliver this service to two other local Jobcentres. This 
commitment was being reviewed regularly in light of any changes in the 
number of referrals being achieved, and in the capacity of the treatment 
provider, to monitor whether his attendance should be increased or reduced. 
Since the trial the treatment provider has been recognised for this work by the 
local DAAT who awarded them a partnership award. The provider also made 
use of his new contacts and organised workshops for unemployed clients on 
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 their Structured Day Programme through the local Next Step20 provider.  
These workshops were held on the provider’s premises and included 
information and advice on career options, CV writing, interview techniques 
and job search advice.  
 
The Lead Drug Champion has been able to continue caseloading substance 
misusing (or potentially substance misusing) customers following the end of 
the trial, and has also continued to give advice and guidance to colleagues on 
identifying and referring substance misusers when needed, raising awareness 
of the agenda amongst all staff. She has attended other JCP offices following 
the end of the IA trial period to share best practice in working with this 
customer group. The Lead Drug Champion was achieving the most referrals 
and starts in the District and as a result was nominated and awarded the 
Regional Employee of the month award.  
 
 
 
 
                                            
20 Jobcentre Plus contracted out employment provision. 
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 4. Qualitative Findings 
 
This section presents the findings from the focus groups and interviews which 
were conducted with key stakeholders in each JCP following the end of the IA 
trial. Stakeholders included the RDSLs, DDCs, Drug Champions and senior 
management as well as front-line staff at the Jobcentres, treatment provider 
staff, and representatives from the D(A)ATs and NTA. The focus groups and 
interviews explored stakeholders’ perceptions of the trial and its impacts, the 
degree of success it achieved, and whether or not it would be sustainable 
over the longer term. Findings are structured according to key themes.  
 
4.1 Initial Reactions 
 
Initial reactions on hearing about the IA trial and what it would involve varied 
across stakeholders and JCP offices. In JCP A treatment provider sessions in 
the office had already been taking place successfully for a number of months 
in advance of the trial, so the prospect of increasing this activity during the 
trial period and raising its profile was largely greeted with enthusiasm and 
positivity by key stakeholders. Nonetheless some front-line staff expressed 
concerns about the additional pressures that might be placed on them as a 
result of the trial. Staff who hadn’t made a referral to a treatment provider or 
who didn’t feel comfortable discussing substance misuse with customers said 
they were particularly worried about what they might be required to do as part 
of the IA trial.  
 
Reactions were also mixed in JCPs B and C, where closer working of this 
nature between their respective offices and the treatment provider was newer 
territory. The RDSL and DDC in JCP B reported feeling very positive about 
the trial and keen to start implementing it, saying that they felt it represented 
an excellent opportunity to try and improve the service JCP provides for 
substance misusing customers. The same stakeholders at JCP C reported 
reacting in a similar way. However, although some front-line staff in JCPs B 
and C were equally positive, as in JCP A others felt more uncertain and had 
concerns about the additional pressure and burden that this project might 
place on them. In the context of the current high customer count being 
experienced at most Jobcentres, these staff felt that they were already being 
asked to do an increasing amount but with limited time and resource, and that 
the IA trial represented yet another demand on the brief amount time that they 
have to see each customer. 
 
Although stakeholders commented that most JCP staff in all three offices 
were on board with the aims of the trial, they also felt that some staff had 
entrenched negative views about substance misusers which would be difficult 
to change, and which meant they were less likely to engage positively in the 
trial. Some front-line staff also voiced the concern that substance misusing 
customers might become violent at the Jobcentre if they felt they were being 
targeted or pressurised into entering treatment. 
 
The treatment providers in JCPs B and C reported feeling both positive and 
enthusiastic about the new challenge presented by working more closely with 
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 Jobcentre Plus, but also apprehensive due to the reputation that JCP has 
amongst their colleagues for being a very process-driven organisation which 
is un-sympathetic and inflexible to the needs of vulnerable groups such as 
substance misusers. The treatment provider in JCP B also reported being 
slightly concerned about the increase in their workload that the IA trial would 
entail. However, above all they said they were eager to engage with the 
Jobcentre as employment is a key goal in many of the recovery plans they 
produce with clients, and because they would be able to promote and 
encourage the use of their services to individuals who they might not be able 
to reach otherwise. 
 
4.2 What worked well 
 
4.2.1 Treatment provider presence 
The treatment provider presence in the Jobcentre was viewed in a very 
positive way by most stakeholders in all three trial sites, and was perceived as 
being central to any increase in referrals that had occurred during the IA trial 
period. JCP front-line staff reported feeling reassured by the provider’s 
presence in the office, and more comfortable raising the issue of substance 
misuse with customers knowing that the provider was on hand to refer to 
immediately and take over any difficult discussions if necessary. In JCP C it 
was agreed that Advisers did not have to probe the nature of a customers’ 
substance misuse (ie. which substance they were using and the extent of their 
problem) if they did not feel comfortable doing so, and that this could be left 
for the treatment provider to explore with the customer. Stakeholders felt this 
worked well and took pressure off JCP staff. Jobcentre staff in all sites also 
reported feeling that it was easier to sell the services of the treatment provider 
to customers when they knew more about that particular provider, trusted the 
organisation and were familiar with the staff at that service.  
 
The treatment providers in JCPs A and C were both very positive about their 
role in the trial and their attendance at the Jobcentre, perceiving it as having 
been a success. They felt that the Jobcentre was an appropriate and 
productive location for outreach due to the fact that a significant number of 
individuals with substance misuse issues are in receipt of benefits21, and 
therefore that their regular visits to the Jobcentre represented a good 
opportunity to engage such individuals in a discussion about treatment. They 
also felt that, when referrals were made to them during their sessions in JCP, 
the ability to speak to customers then and there when they were willing and 
able to talk reduced the numbers failing to attend such discussions.  
 
The treatment providers in JCPs A and C also mentioned various occurrences 
of JCP staff approaching them to ask questions about substance misuse and 
the services they provide, and were pleased that they could help raise 
awareness in this more informal way (in addition to presentations in meetings 
and training sessions). The treatment provider in JCP C in particular talked 
                                            
21 Estimates commissioned by the DWP of the number of problem drug users in receipt of 
benefits suggests that around 80% of PDUs in England are on benefits: Hay, G., and Bauld, 
L. (2008) Population estimates of Problematic Drug Users in England who access DWP 
benefits. DWP Working Paper No. 46. 
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 about receiving a warm welcome from the majority of staff, and being 
reassured to see so much commitment to the drug and alcohol agenda and 
eagerness to improve their skills in working with this customer group.  
 
The treatment provider in JCP A faced no restrictions on the activity they 
could undertake whilst in the Jobcentre, and were able to independently floor-
walk and approach customers to discuss their services, man a desk at the 
front of the office with their literature and leaflets, and make customers aware 
of their presence. The provider was very positive about this freedom and 
recorded engaging with just under 400 customers about their services during 
the course of the trial. Due to restrictions resulting from the TU risk 
assessment, the treatment provider at JCP C on the other hand was not 
allowed to approach customers, identify themselves as a treatment provider to 
customers (at least at the start of the trial) or display their literature and 
posters on a desk. Instead they were required to stay in a private room during 
the majority of their sessions in the Jobcentre. These restrictions were 
described by the provider as frustrating, however the DDC and front-line staff 
in JCP C noted that the treatment provider remained very visible by keeping 
the door of their private room open and maintaining excellent communication 
with staff. The restrictions didn’t prevent the trial from being perceived as 
highly successful in this JCP and achieving an increase in the number of 
disclosures and referrals taking place, which was credited by some 
stakeholders to the proactive attitude of the treatment provider (see Chapter 
5). 
 
The treatment provider staff who conducted the sessions in JCP B were less 
positive about their experience during the trial and about the suitability of a 
Jobcentre as an outreach location, although their manager and the DAAT 
representative did feel there was value in their having a presence in the JCP. 
Their dissatisfaction largely revolved around the restrictions placed on them 
as a result of the Health and Safety risk assessment (see Section 4.3.1). 
However, despite this they were still able to talk about positive outcomes 
resulting from their sessions in the Jobcentre, mentioning in particular an 
occasion when a substance misusing customer was referred to them during 
one of their sessions and was identified during that referral discussion as a 
suicide risk. They acknowledged that, when it happened, being able to see 
customers as soon as they were referred had significant benefits for those 
individuals. A member of JCP B staff also commented that those customers 
who were referred during the trial frequently ask to see the treatment provider 
again when they were in the Jobcentre so that they could update them on 
their progress and seek further help. 
 
Initial concerns that customers might react negatively to the treatment 
provider presence proved to be largely unfounded. Staff in JCP C reported 
that, although some customers were slightly wary of the treatment provider at 
first, after getting used to them they were generally unfazed by their presence 
in the Jobcentre and had no negative feedback about it. Front-line staff in JCP 
B only recalled one situation where a customer had objected to the drug 
treatment leaflets on their desks, but said this was a relatively minor incident. 
Even in JCP A where the treatment provider approached customers to 
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 discuss their services, only one negative customer reaction was recorded and 
again this was perceived as being minor. The provider said that their 
approach – discussing their service, and explaining that the customer in 
question may benefit from knowing about it as they may have friends or family 
with substance misuse issues – worked well and didn’t seem to cause any 
offence in the vast majority of cases. In fact, staff in JCP A reported that the 
treatment provider presence, in conjunction with the outreach sessions by a 
member of Jobcentre Plus staff covered later in this section, actually helped to 
markedly improve the behaviour of a couple of substance misusing customers 
who had previously acted aggressively towards JCP staff.  
 
However, all three treatment providers raised concerns about resource and 
the time they could commit to the Jobcentre sessions in the longer term. This 
issue is addressed in Section 4.5.2. 
 
4.2.2 Closer working / familiarisation period 
Over and above the regular treatment provider presence in the JCP, 
stakeholders felt that closer working between the two organisations was 
proving beneficial for the customers involved with both services. In JCP B the 
familiarisation period – during which the treatment provider spent time with 
JCP staff, exchanged information about their roles and organisations, joined 
team meetings and observed Adviser interviews with customers – was 
described as a ‘two way learning-process’. As a result of this activity the 
treatment provider reported having a far better and more informed 
understanding of the way in which Jobcentre Plus operates and the pressures 
that staff are under, and consequently more sympathy for the aims and 
motivations of the organisation and its staff. The treatment provider at JCP C 
was also very positive about the familiarisation period which he felt enabled 
him to adapt to working in a more formal environment than those in which he 
was used to conducting outreach. He also felt it provided him with the 
opportunity to speak to staff and ‘get his face known’. As discussed in the 
previous section, JCP staff across the three trial sites felt that their greater 
familiarity with the treatment provider and understanding of the services they 
offer made them more likely to recommend a referral to their customers.  
 
The treatment provider in JPC C reported having a greater knowledge of the 
services that the Jobcentre can offer its clients following the IA trial, and 
therefore being better able to make clients aware of the support that is 
available to them. They also said that their greater knowledge of benefit 
issues, for example in relation to the conditionality which Jobcentre Plus 
places on the receipt of certain benefits (eg. job hunting and fortnightly signing 
in the case of JSA), had enabled them to provide advice and encouragement 
to their clients around complying with these conditions, and therefore helped 
their clients to avoid facing benefit sanctions. Although they were keen to 
emphasise that they by no means saw themselves as experts in the area of 
benefits and still felt they lacked the knowledge to properly advise clients 
about such issues, they did say that their increased knowledge of applying for 
benefits and the appeals process meant that they were better placed to 
provide them with some general guidance on these issues, and where 
appropriate to provide advocacy on their behalf when dealing with the 
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 Jobcentre. They believed this had helped to resolve or prevent benefit-related 
problems for a number of their clients.  
 
The treatment providers felt that client feedback on the closer working 
involved in the trial had been positive. As a result of the trial, the treatment 
provider at JCP C said that he now encouraged those clients of his service 
who are JCP customers to disclose their substance misuse to JCP, so that 
they can access the additional support on offer. He also delivered a briefing 
session to colleagues at the treatment provider on Jobcentre Plus, the benefit 
system and the support that JCP offers to customers with substance misuse 
issues, to ensure that other staff at the treatment provider (and their clients) 
could benefit from the knowledge he had gained. It’s worth noting though that, 
despite their involvement in the trial, the treatment provider at JCP B said they 
did not think it was their place to advise customers to disclose to the 
Jobcentre. 
 
Some Advisers in all 3 sites expressed an interest in finding out about the 
progress of customers who they had referred to the treatment provider, 
including whether or not they turned up for the referral appointment and 
decided to take up treatment. They felt that being made aware of occasions 
when customers made a real change in their lives as a result of their referral 
would help motivate them and other Advisers to raise the issue of substance 
misuse with customers more frequently. This closer working helped to 
facilitate the sharing of such information between the Jobcentres and the 
treatment providers (where data protection regulations would allow)22. 
 
4.2.3 DDC and Drug Champion contribution 
The DDCs invested a significant amount of concentrated time and energy in 
the IA during the trial period, and stakeholders in all three trial sites 
recognised the contribution they had made to any success the trial achieved. 
Their input included, amongst other activities, raising awareness of the trial 
amongst staff, organising and facilitating the treatment provider sessions in 
the JCP, and (in JCPs B and C) supporting senior management in 
negotiations about the Health and Safety risk assessment. The Drug 
Champions in all sites were also credited with providing the DDC and the IA 
trial with crucial support, as well as recognised for the important roles (in JCP 
A and C) they played in conducting caseloading and outreach activities. The 
Drug Champion at JCP B relayed her experience of a Jobcentre manager 
who initially felt he couldn’t spare staff time to engage with the activity, but 
who, after discussing the aims and need for the IA with the Champion, said 
that her passion had persuaded him of the value and necessity of the 
initiative. As a result of his support stakeholders reported that the teams he 
managed ended up engaging well with the trial and making a valuable 
contribution to it. 
 
All three DDCs spent the majority of their time in their trial JCP office during 
the IA period, and this level of commitment was perceived as integral to the 
                                            
22 Please note that the JCP Joint Working Protocol makes this sharing of information from the 
treatment provider to Jobcentre Plus possible only where a TPR2 form has been signed by 
the customer. 
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 increases in the number of referrals that were seen over this time. However, 
stakeholders recognised that this had implications for the sustainability of the 
IA as DDCs were responsible for promoting the drug and alcohol agenda in 
multiple offices and therefore would not be able to spend the majority their 
time in only one over the longer term. 
 
4.2.4 Outreach in the treatment provider premises 
The Drug Champion in JCP A conducted outreach in the treatment provider 
premises during the IA trial, and received positive feedback from all staff and 
stakeholders (and, according to the treatment provider, service users) 
involved. She was already volunteering at the treatment provider in her own 
time and had to push for the outreach herself, but was supported in this both 
by the DDC and by her manager. According to her manager, an ASM, the 
need for such an initiative was demonstrated by the number of customers who 
knew the Drug Champion from her voluntary work at the treatment provider 
and who approached her at the Jobcentre to ask for her help with their 
benefits and employment issues. The Drug Champion reported feeling 
frustrated prior to the IA trial about not being able to caseload these 
customers or spend as much time with them as she felt they required. 
 
Around a week before the start of the outreach a member of JCP A staff (an 
Adviser in the Lone Parents team) conducted a Health and Safety risk 
assessment at the treatment provider to ensure that the activity would not 
pose any serious risks to the Drug Champion. Adjustments – including 
changing the room the outreach was going to take place in to ensure that its 
set-up provided the Drug Champion with a clear exit route should she need to 
leave during an appointment, and adding a panic alarm to the room for her to 
use if necessary – were requested following the assessment. However, 
following these changes, which were viewed by stakeholders as relatively 
minor, the outreach activity was given approval to go ahead. 
 
After an initial scoping session in which the Drug Champion consulted clients 
about what they wanted to get from the service and what form they wanted it 
to take, which she felt was useful for getting clients on board with the outreach 
service, she saw customers in individual private appointments. This was for 
confidentiality reasons, and to enable them to feel free to discuss anything 
they wanted with her. The Drug Champion reported that she received a 
significant amount of interest in the sessions from substance misusers and 
that she was booked up in advance for every one she held. She found that, 
although they always turned up at some point during her sessions, the 
customers found it difficult to stick to pre-booked appointment times because 
of the often chaotic nature of their lives, so a degree of flexibility on her part 
was needed when conducting these sessions. 
 
The Drug Champion reported that almost every appointment she had with 
customers covered a different issue, ranging from training opportunities and 
CV writing skills to signposting to other services. Although some of the 
appointments were benefit-related, she found that the majority were training 
and employment focused, which was viewed as a positive by stakeholders. 
Customers were allowed to set the agenda during these sessions. She felt 
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 that most appointments led to a positive outcome and progress being made 
for the client, and reported that she even managed to support one customer 
back into employment during the outreach sessions. Both the Drug Champion 
and the treatment provider expressed the view that service users were more 
willing to engage openly with JCP staff when in the more familiar and 
comfortable environment of the treatment provider premises than when in the 
Jobcentre itself, as customers were not afraid of potential stigma or 
discrimination there. Also, because all the appointments were held in a private 
room, the concerns about a lack of privacy in relation to the open plan 
Jobcentre office were removed. 
 
There was consensus between the Drug Champion and treatment provider 
about the qualities that an individual needs to possess if they are to be 
successful in conducting outreach at a treatment provider on behalf of JCP. 
Empathy with and sympathy for substance misusers; an interest in the issues 
surrounding substance misuse; excellent inter-personal skills to enable them 
to develop constructive relationships with individuals who can sometimes 
display difficult behaviour; a passion for helping people; good listening skills 
and a non-judgemental attitude were all considered to be very important. 
Adaptability was also seen to be an important quality to enable Advisers 
conducting outreach to tailor their working style to the less structured and 
target-oriented environment (in comparison to JCP) in which treatment 
providers operate. The Drug Champion also acknowledged that already 
volunteering with the treatment provider, and hence being a known and 
trusted face to the clients, made a significant contribution to the success of 
the sessions. She recognised that gaining the trust of this customer group can 
take time, and mentioned having seen professionals from other organisations 
coming into the treatment provider premises and having a more challenging 
time trying to engage with clients due to the fact that they had no prior 
relationship with them.  
 
The Drug Champion acknowledged that productivity targets, in terms of the 
requirement on Personal Advisers to achieve a certain number of interviews 
and employment or training-related outcomes per week, was a potential issue 
when conducting outreach with substance misusing customers. She did not 
record any details of the outcomes of her outreach appointments on the 
productivity-management system, but felt this was likely to be the next step if 
the outreach was continued. The Drug Champion felt that her role as an under 
18s Adviser, which meant that she had a target of 6 rather than 9 interviews 
per day, made it easier for her to make time to conduct outreach, but that it 
would be more difficult for ‘normal Advisers’ with the higher target to 
undertake such activity. 
 
4.2.5 Training 
During the IA trial the DDCs and treatment providers in all three offices 
organised training of some kind for JCP staff, whether in the form of up-
skilling sessions, interactive workshops, informal one-to-one and group chats 
with Advisers between appointments, or a combination of these. All training 
was delivered by the treatment provider in conjunction with the DDC, and in 
some cases the Drug Champion as well.  
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Despite previous staff training sessions having been held prior to the IA trial, 
DDCs and treatment providers identified a skills gap amongst many JCP staff 
in relation to knowing how to raise the issue of substance misuse with 
customers for the first time and sensitively ask the question about whether 
this is a barrier to employment for them. They therefore aimed to address this 
in their training. Other issues covered ranged from general awareness of 
drugs and treatment, identifying possible signs of substance misuse, what to 
say when a customer discloses substance misuse and the ‘can of worms’ has 
been opened, and how to diffuse tension with difficult customers, to selling the 
benefits of a referral to a treatment provider to customers, correctly referring a 
customer, and knowing what impact (if any) a particular treatment regime will 
have on a customer’s ability to undertake work, generally and in relation to 
specific jobs. 
 
Stakeholders reported that the training helped to break down Advisers’ 
concerns about addressing substance misuse with customers – as well as 
any negative preconceptions around the kind of person who becomes a 
substance misuser – and had given them the confidence and tools to broach 
the issue with customers where necessary. Front-line staff reported that the 
training had made them more aware of what to ask and when, and how to 
make a referral to the treatment provider. However, despite the positive 
impact that training had in all JCP trial sites, several members of front-line 
staff still reported having concerns about addressing substance misuse with 
customers even after attending training. Additionally, due to the heavy 
workload of many Advisers and the emphasis on productivity, not all staff 
were released to attend the formal training sessions. It is due to these 
limitations around training and Adviser confidence that stakeholders in JCP C 
felt caseloading to a dedicated Adviser has an important role in working with 
this customer group (see section below). 
 
4.2.6 Caseloading to a dedicated Adviser 
In JCP C, the practice of caseloading customers with known or suspected 
substance misuse issues to one Adviser was felt by stakeholders to have 
worked very well from the customer relationship perspective. The Adviser who 
volunteered for the role of Lead Drug Champion and was responsible for 
caseloading these customers was very enthusiastic about working with them, 
had an easy rapport with them and said she felt very comfortable raising 
issues around substance misuse. As a result she was able to have productive 
discussions about the situation and support needs of these customers during 
her appointments. The customers themselves were said to be developing 
greater trust in JCP as a result of the strong relationship they were building up 
with the Drug Champion, and in turn she said that she found helping these 
customers to make progress very fulfilling. Her practice of following up 
customers who had been referred to the treatment adviser to check whether 
they had attended and how they got on was also reported to be working well.  
 
The treatment provider and DDC at JCP C were very positive about the 
practice of caseloading customers to a specific Adviser who has the 
motivation and people skills to work effectively with this group, as well as the 
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 additional flexibility to see these customers for the longer and more regular 
appointments they often require, free from the standard productivity targets. 
Both felt that developing the role of a Specialist Adviser within JCP who could 
caseload substance misusing clients would elicit the best results for this group 
in the longer term. Other JCP front-line staff, some of whom said they weren’t 
comfortable discussing the issue of substance misuse with customers despite 
the training and upskilling they had participated in, said they thought such a 
model would be a better way of working with this customer group than 
expecting all front-line staff to have the skills to work effectively them.  
 
The Lead Drug Champion in JCP A, although unable to caseload substance 
misusing clients in the Jobcentre in addition to conducting outreach at the 
treatment provider premises, said she felt such a system would be a very 
good idea. She believed that there would be significant demand for it, based 
on the number of substance misusers she knew from the treatment provider 
who came into the Jobcentre and asked to see her about their employment or 
benefit-related issues.  
 
However, the Lead Drug Champion in JCP C did raise issues around the 
conflict between productivity measures and caseloading substance misusing 
customers, which has implications for the longer-term sustainability of such 
activity (see Section 4.3.2 below). 
 
4.2.7 ‘Are you missing out?’ form 
The use of the locally produced ‘Are you missing out?’ form (see Appendix C) 
was, in the main, viewed positively across all three sites as way of helping 
Advisers to elicit information about whether drug or alcohol abuse is a barrier 
for customers. This was a locally produced form, and its format varied 
between the three sites although its content was the same. It was considered 
particularly useful as it did not deal with substance misuse in isolation, but as 
one of a number of possible barriers (including disability and low 
qualifications). It was also perceived as helping to overcome to some extent 
the issue of lack of privacy in JCP, which can lead to customers feeling 
inhibited about disclosing their substance misuse problems due to the 
concern that other customers might overhear, because customers could just 
tick a box on the form rather than talking about their issues out loud.   
 
However, not all JCP staff felt that the form was useful. In JCP A views were 
mixed: those front-line staff in Stage 1 teams working with new customers and 
those using it in group sessions found it useful, but those Advisers using it 
with Stage 3 customers reported finding it awkward. They felt that by that 
point in the customer journey the Jobcentre should know what barriers a 
customer has, and thought that customers found it strange and untimely that 
they were being asked about barriers at that point. As such they felt that the 
use of this form could damage the trust and confidence they had built up with 
the customer. JCP A and C staff agreed that using the form with new 
customers, for example in Back to Work group sessions, was more 
appropriate than using it with longer-term customers. In JCP C around one 
hundred and fifty forms were completed during the course of the trial, but drug 
and alcohol issues were only identified as a barrier in ten of these. This was 
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 surprising given that a substantially higher number identified a criminal record 
as a barrier and the prevalence of substance abuse is high amongst offenders 
and ex-offenders. Stakeholders felt it could indicate that, despite the form, 
customers were still not declaring their substance misuse problems in many 
cases. JCP C front-line staff also reported that many customers did not 
complete the forms as they weren’t mandatory. This led to the conclusion, as 
expressed by the treatment provider at JCP C, that the form is useful as a 
springboard into a discussion about substance misuse issues with customers 
in the early stages of their claim, but is not a substitute for Advisers actually 
asking customers the question. 
 
4.2.8 Other positive processes and activities 
Across all the trial sites, the leaflets about substance misuse and treatment – 
including the FRANK and JCP leaflets, as well as those produced by the 
treatment providers involved in the trial – were seen as a positive addition to 
the information that JCP already provide. They were seen to allow customers 
to take away and mull over the information, and also, in JCP A, were reported 
to have aided self-referrals to the treatment provider for customers who did 
not want to disclose drug use to JCP staff. Front-line staff in JCP B 
commented on the number of FRANK leaflets that were being taken from their 
desks even when the issue of substance misuse had not come up during the 
appointment. In fact, demand for them was so high that additional supplies of 
the booklets had to be found mid-way through the trial.  
 
It was agreed across JCPs B and C that it was better to be able to display the 
leaflets (and other material) on Adviser’s desks and in a dedicated area rather 
than in a stand along with other materials where they aren’t as prominent. The 
DDCs and RDSLs expressed disappointment that the JCP leaflets about 
referrals and other services for substance misusing customers, including the 
progress2work employment programme, were no longer being produced due 
to financial restrictions. In JCP A their solution to this was to photocopy the 
leaflet and distribute the copies. 
 
Another common view across the trial sites was that having a private room in 
the JCP in which to engage with customers who have disclosed substance 
misuse is essential in order to ensure they are comfortable discussing 
personal and sensitive information without fear of being overheard by other 
customers. Where such a space was available for the provider most of the 
time during the trial, for example in JCPs B and C, this worked very well, 
however this was more problematic in JCP A where there was a shortage of 
private rooms. It should be pointed out that the providers also valued being 
able to sit at a desk in the main office space while not seeing customers 
rather than just a private space or back room, so that they could make staff 
and customers aware of their presence. 
 
In JCP C, the practice of the DDC previewing customers’ LMS records for 
signs of possible substance abuse issues and flagging these up to the Adviser 
was deemed to work well, although it was acknowledged to be very resource 
intensive for the DDC and probably not sustainable in the longer term. The 
Adviser question and answer sheet (Appendix D), drug quiz (Appendix E), 
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 and referral walk-through sessions and memory aid (Appendix F) also 
received positive feedback in terms of helping to increase awareness and 
confidence amongst staff, and were viewed to be more feasible as part of a 
longer-term activity. 
 
In JCP A case-conferencing within teams – ie. the opportunity to discuss 
individual customer cases where substance misuse is suspected as being a 
problem with the ASM and other team members – was viewed as having a 
positive effect on advisers’ confidence around raising the issue with 
customers. 
 
4.3 What worked less well / problems encountered 
 
4.3.1 Health and safety risk assessments 
As discussed in Chapter 3, the Health and Safety risk assessments which 
were required prior to start of the treatment provider sessions in JCPs B and 
C were identified as one of the main obstacles encountered during the trial in 
these areas. Stakeholders in both areas reported that the Trade Union 
representatives who were responsible for conducting the assessments had 
not been supportive of the plan to introduce a treatment provider presence 
into the Jobcentre. They had raised concerns about the activity being likely to 
attract large numbers of substance misusers to the office, and to potentially 
compromise the safety of JCP staff if they became a target for drug dealers 
who felt they were helping to take away their business23. Both the treatment 
providers and DDCs felt that that these fears were unfounded, and that they 
were a result of limited knowledge and experience in the area of substance 
misuse. The treatment providers expressed frustration that neither they, the 
local D(A)AT or a different, impartial treatment provider in the area were 
approached by the TU representatives for advice and guidance around this 
issue before the risk assessment was completed, and that the TU 
representatives seemed unwilling to engage in dialogue with them about 
strategies for minimising the risks they had raised. However, the DDCs and 
other stakeholders acknowledged that they had not had as much time as they 
would have liked during the development of the trial to properly engage the 
TU representatives in discussion, due to the tight timescales they were 
working to. 
 
The result of the assessments in JCPs B and C was that significant 
restrictions were placed on the range of activities that the treatment providers 
could undertake whilst in the office24. In JCP B the treatment provider staff 
were not allowed to approach customers or identify themselves as treatment 
workers even when asked, and were similarly not allowed to wear their ID 
badges. This lead to difficult situations in which they (and JCP front-line staff) 
felt they were deceiving customers about their real role and the reason for 
                                            
23 Please note that these views represent the perceptions of key stakeholders involved in the 
trial rather than those of the TU representatives themselves. 
24 These restrictions are not reflective of Jobcentre Plus (or DWP) Health and Safety Policy, 
which allows for such activities to take place provided that suitable risk assessment 
processes have been followed and any necessary control measures or risk mitigations put in 
place, but instead were a result of decisions taken at the local Jobcentre Plus office level. 
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 their presence in the JCP. They were initially prevented from making 
customers aware of their presence - for example by setting out leaflets, 
posters or banners, or manning a desk on the office floor - and spent their 
time during their sessions sitting in a private room. They reported that as a 
result customers often did not realise they were there, but also that staff were 
frequently unaware of their presence as well. This also highlighted a problem 
with communication, which is explored in Section 4.3.3. The treatment 
provider in JCP B felt that their lack of visibility had a negative impact on the 
number of customers who disclosed their substance misuse and were 
referred to them during the trial period.  
 
Additionally, the treatment provider staff in JCP B were asked to comply with 
JCP office dress codes as their usual dress was seen to be inappropriately 
informal for the Jobcentre. This caused problems for the treatment provider 
staff who wear more casual clothes in their role so as to create an 
approachable and comfortable atmosphere for their clients, and they reported 
feeling undermined and belittled by this request.  
 
During the first week of the trial in JCP B, it was reported that an email was 
sent to staff from the TU representative informing them that they weren’t 
allowed to ask customers about substance misuse issues. Although asking 
about such issues in the context of barriers to work is allowed, this email was 
said to have caused a lot of confusion and uncertainty and made some staff 
reluctant to engage with the trial.  
 
The treatment provider similarly reported that, as a result of receiving what 
they perceived to be a hostile reception from the Health and Safety risk 
assessment, they felt very cautious about ‘overstepping the mark’ during their 
sessions in the Jobcentre. They said that the initial enthusiasm they had felt 
about the trial started to wane as a result of the obstacles they faced posed by 
the risk assessment, and the feeling that their presence was not welcome in 
the JCP office. They felt that their resource and skills were being wasted while 
they sat in a private office, only seeing a very small number of customers 
despite the extensive time they were spending in the JCP. The treatment 
provider felt that four sessions a week was excessive given the number of 
referrals they were getting. These experiences led to some of the treatment 
provider staff in JCP B concluding that a Jobcentre is not a suitable location 
for outreach with substance misusers. Front-line staff in JCP B also reported 
feeling frustrated and disappointed that the treatment provider resource was 
not made better use of during the trial. 
 
As a result of negotiations by Senior Managers, the DDC and Drug Champion 
in JCP B half-way through the trial, the TU representatives agreed to conduct 
another risk assessment with someone from the DAAT present. This resulted 
in some of the original restrictions being lifted. However, stakeholders 
generally felt that the relationship between JCP and the treatment provider 
had already been damaged by that point and that, although things had started 
to improve slightly as a result, the negative impact it had had on the success 
of the trial could not be reversed in the remaining four weeks.  
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 The situation in terms of restrictions was similar in JCP C. The treatment 
provider expressed frustration that he was not allowed to approach customers 
and discuss his work with them as he felt that this was where his skills as a 
specialist outreach worker really lay. However, as an outreach worker 
experienced at working in structured environments (such as prisons) he was 
very proactive in his role, and managed to ensure that he made customers 
and staff aware of his presence, despite being in a private room, by always 
leaving the door open when he wasn’t seeing customers, and taking every 
possible opportunity during these times to talk to and sit with staff. Despite 
consensus that this was not an ideal situation, stakeholders in JCP C 
confirmed that the TU restrictions did not seem to have had a significant 
detrimental effect on the success of the trial. 
 
In both JCPs B and C, the risk assessment also prevented the Drug 
Champions from visiting the treatment provider premises and an outreach 
project in a hostel as part of their training. JCP staff and the treatment 
provider in both sites reported frustration about this as they valued the 
importance of such activity in helping staff to better understand the situation 
that substance misusers face. 
  
Conversely, in JCP A the treatment provider was allowed to approach 
customers, make them aware of their role and promote their presence. It was 
not necessary to conduct an additional risk assessment at the start of the trial 
relating to the treatment provider presence as this represented the 
continuation of pre-existing activity. However, before the sessions began 
(around 8 months prior to the IA trial) the existing office risk assessment was 
reviewed to ascertain whether any additional safety measures would have to 
be put in place. The existing risk assessment already covered third party staff 
attending the JCP and interacting with customers, and the decision was taken 
by the TU representative that having treatment providers on site did not pose 
any additional risks over and above those already covered in the assessment. 
A risk assessment was, however, conducted prior to the start of the JCP 
outreach sessions at the treatment provider premises. The assessment was 
reported to work well and had a positive outcome which supported the activity 
(see Section 4.2.4 for more details). 
 
4.3.2 Adviser productivity 
In all three JCP sites, conflict between Advisers’ productivity targets (in 
relation to interviews per day and customer starts to employment and training) 
and their involvement in the trial was raised as a potential barrier to the 
success of the IA. It was generally agreed by senior managers as well as 
front-line staff that the trial did not place significant burdens on the majority of 
Advisers. However, front-line staff reported that they were concerned about 
raising the issue of substance misuse with customers in case it led to a 
disclosure and a lengthy discussion which dominated the rest of the 
appointment and prevented them from addressing other necessary issues, or 
made the Advisers late for their subsequent appointments. Those Advisers 
who were concerned about this said that the knowledge that they would be 
able to make an instant referral to the treatment provider during their sessions 
in the office who would be able to take over the conversation helped to allay 
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 these concerns, and again confirmed the value of the treatment provider 
presence in JCP.  
 
Productivity targets were a more significant issue for the Drug Champions in 
JCPs A and C who were respectively responsible for conducting outreach 
sessions in the treatment provider premises and caseloading substance 
misusing customers. They both discussed the challenges of achieving their 
standard targets when also devoting a set amount of time to working with 
substance misusing customers who, they agreed, require significantly more 
intensive and extended support than the majority of customers to achieve the 
same outcomes. The Drug Champion in JCP A had a lower target number of 
interviews due to being an under 18s Adviser, and for this reason felt it would 
be realistic for her to continue with the outreach sessions after the end of the 
trial. The Lead Drug Champion conducting caseloading in JCP C similarly 
found it difficult to achieve her targets whilst devoting one afternoon a week to 
this activity. At the time of the fieldwork she wasn’t sure whether, as a result of 
this, she wouldn’t be able to continue with the caseloading activity following 
the end of the trial period, although it later transpired that she was allowed to 
do so. 
 
As mentioned in Section 4.2.5, operational pressures affecting Advisers’ 
workloads had an impact on whether they were released to attend substance 
misuse training sessions. Across all three JCP sites it was acknowledged that 
they often meant staff were not able to attend such training even when they 
felt that they didn’t have the necessary skills to work effectively with this 
customer group. 
 
4.3.3 Communications 
Having effective communications around the trial within the JCP was 
something that proved to be a problem in JCPs B and C. Due to the lack of 
all-staff meetings in both JCPs, the DDCs in both sites said that they found it 
problematic finding the right platform or channel through which to raise 
awareness of the trial and the treatment provider’s presence amongst all staff. 
Although the DDCs and treatment providers gave presentations about the trial 
at early morning spotlight sessions, not all staff attended these. Additionally, 
the DDCs felt that emails they sent out to all staff to notify them of the days 
and times of the treatment provider sessions were overlooked because the 
volume of emails that JCP staff received and the pressures on their time 
meant that they weren’t able to properly engage with them. Smaller team 
meetings were seen as an effective (if more time consuming) forum for 
awareness raising around the trial, but where the team leaders weren’t on-
board with the aims of the IA and didn’t view it as a high priority (see Section 
4.3.4) they were not prepared to devote time in their meetings to a discussion 
of it. In JCP B the treatment provider said that, six weeks into the trial, they 
were still coming into contact with staff who didn’t know who they were or 
what they were doing in the JCP office. The DDC in JCP C felt that the activity 
lacked the high profile launch that would have maximised the trial’s chances 
of success.  
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 Communication appeared to be less of a problem in JCP A due to the fact that 
the provider had been attending the Jobcente for about 8 months prior to the 
start of the trial and was therefore already well known to most staff, and 
because they were allowed to have a far more visible presence on the office 
floor than the provider in the other two trial sites. 
 
4.3.4 JCP management buy-in 
Stakeholders in JCP B felt that they faced difficulty in securing buy-in from all 
JCP managers to the aims and objectives of the trial. They felt that this was in 
part due to the short lead-in time for the trial and hence the lack of time to 
discuss the activity with these individuals and convince them of its 
importance, and also due to the crowded nature of the agenda and the 
operational pressures currently being experienced in JCP. The stakeholders 
felt that, where they were not able to secure the support of a manager, the 
teams for which they were responsible ended up not engaging with the trial as 
they did not have the support or encouragement to do so from their senior 
colleagues. As a result the stakeholders believed that it was significantly 
harder to make those customers dealt with by the teams in question aware of 
the trial and the treatment provider presence in the JCP than it was those 
customers dealt with by teams whose ASMs were supportive of the trial.   
 
4.3.5 Other elements that worked less well 
Two other areas which were highlighted as being problematic concerned the 
setting of disadvantage and pilot markers following customer disclosures 
about substance misuse, and the lack of privacy within the JCP for sensitive 
discussions with customers. In relation to disadvantage markers, stakeholders 
in JCP C voiced the concern that undermarking was happening, in other 
words that although customers were disclosing their substance misuse to 
Advisers the LMS markers recording these disclosures were frequently not 
being set. This was despite the DDC in JCP C producing a referral process 
memory aide for Advisers for use during the trial, and talking them through the 
process in one-to-one sessions. The DDC and RDSL in particular felt that this 
was happening because the process for making a voluntary referral to a 
treatment provider is too complex and time consuming, requiring staff to 
complete a data protection form, set a disadvantage marker on the system 
and also an additional marker indicating treatment status if the customer is a 
PDU. These stakeholders were strongly of the view that the process needs to 
be simplified if a decrease undermarking is to be achieved. 
 
The lack of privacy in JCP for sensitive conversations with customers, such as 
those about substance misuse, has been previously found by research to be 
one of the elements of JCP that drug misusers are uncomfortable with25. The 
issue emerged again during the IA trial, with the treatment provider in JCP A 
citing this as one of the reasons why they felt some substance misusing 
customers did not want to take up the opportunity of a referral to them in the 
JCP office. In JCP A, although the treatment provider was given a lot of 
freedom to approach customers, they were not allocated a private room (as 
                                            
25 Bauld, L., Hay, G., McKell, J., and Carroll, C. (2010) Problem Drug Users’ experiences of 
employment and the benefit system. DWP Research Report No. 640 
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 the treatment providers in JCPs B and C were) due to the lack of availability of 
such rooms in the office. They expressed the opinion that the trial would have 
been more successful had they been able to speak to people about their 
substance misuse in an area away from other customers where their 
discussion could not be overheard. 
 
4.4 Overall success 
 
Stakeholders were asked about their perceptions of the success of the IA trial 
as a whole in their JCP. Views were mixed, and there was acknowledgement 
that the trial periods were relatively short and therefore that any success seen 
during that time represented only the start of what could be achieved over the 
longer term, were the activity to continue. However, on the whole 
stakeholders – especially those in JCP A and C – were very positive about the 
overall impact of the trial, identifying several key areas which they believed 
had improved significantly as a result of it. They did acknowledge though that 
the issues around the Health and Safety risk assessment had affected their 
perceptions of the success of the trial, and that the success had not always 
been reflected by the number of referrals and disclosures achieved.  
 
4.4.1 Confidence, motivation and skills of JCP staff 
Stakeholders across all sites felt that, through a combination of training, 
awareness raising and additional support for staff, many Advisers and other 
front-line staff had become more actively involved in the substance misuse 
agenda and more comfortable with discussing such issues with customers. 
Stakeholders in JCP A cited the fact that referrals had been made during the 
trial period by four members of staff who had never previously made one as 
evidence that greater numbers of staff were engaging than was previously the 
case. Stakeholders in JCP B said that the process of breaking down Advisers’ 
concerns and building their confidence in this area would necessarily be a 
gradual one, but that the various activities involved in the trial had gone a 
significant way to achieving this aim. They did acknowledge that some staff 
(including some ASMs) were still not on-board with the aims of this agenda, 
and indeed some front-line staff interviewed said they still weren’t comfortable 
discussing these issues with customers and wanted to leave this task to the 
Drug Champion and DDC. However, most stakeholders nonetheless felt that 
the IA had resulted in significant progress being made in this area.  
  
4.4.2 Improvement in service and relationships with substance misusing 
customers 
Stakeholders in JCP A in particular, although also in JCP C, felt that there had 
been a noticeable shift in the attitudes of substance misusing customers 
towards JCP since the start of the trial, from quite a hostile and negative – 
and sometimes aggressive – position to a more positive one. They felt that as 
a result of staff becoming more aware of and sympathetic to the support 
needs of this customer group, and as a result of the visible presence of the 
treatment provider at the Jobcentre and vice versa (during the JCP outreach 
sessions), the behaviour of substance misusing customers had improved and 
they were starting to engage with JCP in a more open and productive way.  
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 The treatment providers in JCPs A and C were very positive about having a 
presence in the Jobcentre, and felt that as a result of it they were able to 
access individuals who they hadn’t come into contact with before. They 
acknowledged that a significant proportion of substance misusers are in 
receipt of benefits and that the Jobcentre is often the only organisation that 
they will visit on a regular basis, making it an ideal place to offer information 
and advice about treatment. Both treatment providers were keen to continue 
with their sessions in the JCP (albeit in a reduced frequency – see Section 
4.5.2) and the treatment provider in JCP C was also in discussions about 
extending the service to other JCP offices in the area, demonstrating their 
belief that this model of closer working with JCP has definite benefits for them 
and for substance misusers. The treatment provider staff in JCP B, however, 
were less certain that the Jobcentre represents a good place in which to try 
and engage substance misusers, citing the problems they experienced in 
relation to the risk assessment as evidence that key JCP staff do not want to 
get involved in the substance misuse agenda, making it very difficult for the 
two organisations to work together in a productive way.  
 
4.4.3 Risk assessment issues 
Although both JCPs B and C had restrictions placed on the trial as a result of 
the Health and Safety risk assessment, when considering overall success 
only stakeholders in JCP B felt that it had a significant and lasting negative 
impact on the trial. The treatment provider and JCP front-line staff in particular 
felt that, although the trial had represented an excellent opportunity for the two 
organisations to work together more closely to support substance misusers, it 
ended up being a missed opportunity as the treatment provider was very 
limited in the activities they could undertake, and due to the small number of 
referrals achieved ended up not being able to spend the majority of their time 
in the JCP in a productive way. Stakeholders felt that if the issues around the 
risk assessment had been resolved earlier then the trial in JCP B would have 
been more successful. 
 
4.4.4 (Limited) increases in disclosures and referrals 
Across the three trial sites, very different outcomes were achieved in terms of 
the numbers of disclosures and referrals which took place during the trial 
compared to those which had been recorded prior to it. Stakeholders in JCP C 
were very positive about the increase in numbers that they had seen during 
the trial and felt that the IA had been key to driving these up. However many 
in JCP B (and to a lesser extent JCP A) acknowledged that they didn’t feel the 
increases seen in these hard outcomes reflected how successful they 
believed the trial to be. There was widespread agreement that capturing 
success in terms of hard outcomes was difficult, but that that the success of 
the IA trial should not be measured in terms of these figures alone, but also 
according to other ‘softer’ measures including, for example, staff motivation 
and confidence.  
 
As touched on at the beginning of this section, stakeholders were also keen to 
point out that they felt that 4-8 weeks was a very short amount of time in 
which to see the sort of culture change (both within the JCP and in substance 
misusers attitudes towards the JCP) which the IA would have to achieve 
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 before it started to see significant increases in disclosures and referrals. Many 
expressed confidence that if the IA were to be continued they would see a 
steady increase in the numbers of customers opening up about their 
substance misuse and accepting the offer of a referral to the treatment 
provider as the message spreads within the substance misusing community 
about the support that JCP can offer them.  
 
4.5 Sustainability over the longer term 
 
Stakeholders were asked about how sustainable the IA would be in the longer 
term, and whether they were planning to continue with the activity after the 
end of the trial period. 
 
4.5.1 JCP perspective 
In terms of JCP staff resource, the main individuals whose workload saw an 
increase as a result of the trial were the DDCs and the Drug Champions, in 
particular those Champions who took on the responsibility of conducting 
outreach sessions in the treatment provider premises and caseloading 
substance misusing customers. The DDCs in all areas spent the majority of 
their time in the trial site JCP during the trial, and they acknowledged that this 
wouldn’t be sustainable in the longer term as they are responsible for the 
substance misuse agenda in more than one JCP office. However, they felt it 
would be valuable and realistic (from their perspective) for the IA to continue 
but with less intensive support from them now that it was more established 
and the initial bedding in phase was coming to an end.  
 
The Drug Champion in JCP A was keen to continue with the treatment 
provider outreach and, following agreement from her ASM, was planning to do 
so. However, she said that a solution to the issue of how to incorporate this 
activity into her productivity targets would have to be considered if the 
sessions were to become a more permanent aspect of her job. The Lead 
Drug Champion in JCP C similarly continued to caseloaded substance 
misusing customers following the trial, although she acknowledged that the 
struggle to achieve her targets whilst also undertaking this activity would be 
ongoing. 
 
4.5.2 Treatment provider perspective 
The sustainability of the IA for the treatment providers varied, but each was 
downscaling the amount of time that they spent in the Jobcentre following the 
end of the trial. For the treatment provider in JCP A, this meant reducing their 
attendance from three to one session a week, back down to what they were 
committing to the activity prior to the start of the trial. They reported that, 
although they felt IA was a productive use of their time, resource constraints 
meant that they could not spare staff for three sessions a week on an ongoing 
basis. In JCP B the treatment provider stopped regularly attending the 
Jobcentre following the end of the trial but said they were prepared when 
possible to offer a more responsive service and come into the office to meet 
with customers when any voluntary referral appointments were scheduled in. 
From their perspective four sessions in the JCP per week had not represented 
a good use of their time when combined with the limitations imposed on their 
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 activity whilst in the office, and what they felt were the low number of referrals 
achieved during the trial. They pointed out that, although the softer measures 
of success, such as improved working relationships, are important, without a 
significant increase in the number of referrals taking place they would find it 
very difficult to justify spending a substantial amount of time in the JCP to their 
commissioners.  
 
In JCP C, the treatment provider was very positive about maintaining a 
presence in the Jobcentre, but was also having to reduce his time in the 
office, in this case halving it to one session a week. This was due to his 
commitments to other outreach projects which meant he had less time to 
spend at the Jobcentre. However, he also planned to try and offer a more 
responsive service and come down to the office to see a customer as soon as 
they had been referred if at all possible. He had additionally expressed an 
interest in the possibility of extending the service to other JCP offices in the 
area (time and resources permitting), and the feasibility of this was being 
discussed by the provider and commissioning D(A)AT at the time of the 
fieldwork. 
 
4.6 Key lessons and advice 
 
Stakeholders were asked for the top pieces of advice, or the most important 
lessons they had learnt during the trial, which they would want to pass on to 
other JCP offices and treatment providers who are about to adopt a similar 
model of closer working. While the pieces of advice covered a broad range of 
issues, some key themes emerged.  
 
4.6.1 Preparation and planning 
The first theme was the importance of conducting full and proper planning in 
advance of the introduction of IA, and getting various key parties on board 
with the objectives of the activity early on in its development. Stakeholders in 
JCP B particular felt they had been required to introduce the trial very quickly 
and without a reasonable lead-in time, and as a result had not had the 
opportunity to engage with some of the key stakeholders, including TU 
representatives, as early and in as structured a way as they would have liked. 
They felt that this then led to problems during the trial which could have been 
resolved prior to its start had they had the proper discussions with 
stakeholders and secured their buy-in early on.  
 
It was also seen as important to engage with the treatment provider at the 
earliest possible opportunity so that the IA can be co-designed in conjunction 
with them, and so that the roles of both JCP and treatment provider staff in 
the trial can be agreed and clarified at the start to prevent any 
misunderstandings or false expectations.  
 
4.6.2 JCP senior management buy-in 
Linked to the theme above, stakeholders in all three sites also felt strongly 
that it is important to get buy-in from an early stage from the JCP office senior 
managers and team leaders. They felt that it is necessary to get these 
individuals, along with any other ‘key influencers’ that have been identified in 
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 the JCP, on-board with the aims of the IA in order to maximise the chances of 
all teams within the office participating fully in the activity, and to ensure that 
the IA doesn’t lose momentum following the initial, more intensive phase.  
 
4.6.3 Intensive start and good communications 
Some of the key stakeholders in JCPs B and C, including the DDCs, felt that 
having an intensive start to the IA, or what the DDC in JCP C described as a 
‘big bang’ start, was very important to maximise its chances of success. Both 
the DDCs acknowledged that the trials in their JCPs had not had the easiest 
of starts due to the issues around the risk assessment and with 
communications, and felt that this had negatively impacted on the subsequent 
success of the trial (although more so in JCP B than C). The treatment 
provider in JCP C said he would stress the importance of spending the initial 
few weeks of the trial really getting to know JCP staff and developing strong 
working relationships and trust with them. He said that he did this by taking 
every opportunity he could to speak to and engage with staff members, 
including attending team meetings and having conversations with them when 
they were between appointments, as well as spending his breaks in the staff 
room every day and talking to them on a more informal basis. The DDCs for 
their part emphasised the importance of having the DDC (or the member of 
Jobcentre Plus staff who has responsibility for the main functions of this role) 
spend the majority of their time in the JCP office in which IA is being 
introduced during the first few weeks of the activity if possible. 
 
Linked to this advice about an intensive start is that which stakeholders gave 
around the importance of good communications within JCP, especially during 
the early stages of any IA initiative. They stressed the importance of 
promoting and raising awareness of the trial to all staff so that everyone is 
aware of what is taking place, of the importance of substance misuse issues 
within the broader JCP agenda, and of the opportunity they can offer to 
customers of an immediate referral to the treatment provider during the 
provider’s sessions. The treatment provider in JCP B had the experience that, 
as a result of difficulties around communication within the office, some staff 
were not aware of the times and days they were going to be present in the 
office, and indeed reported that there was occasionally uncertainty amongst 
JCP staff about whether or not they were in the office at the present time. 
They therefore suggested having a chart on the wall of the staff room listing 
the dates and times of the provider sessions for the upcoming week, along 
with their location if the provider is going to be situated in a private room 
rather than floor walking or sitting at a desk on the office floor. 
 
4.6.4 Training 
There was agreement that training for JCP staff is a key element of IA and 
crucial in helping to tackle any negative perceptions and stereotypes staff may 
have in relation to substance misusers, give staff the skills they need to 
confidently raise and deal with the issue of substance misuse with customers, 
and understand any limitations that treatment places on an individual’s 
capacity to undertake employment. They felt it was particularly important that 
all staff attend such training if a ‘whole office’ approach is to be taken with 
regards to this agenda, ie. if all staff are going to be expected to work with 
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 substance misusing customers take an active role in the agenda, rather than 
just specialist advisers (or Drug Champions). Initial awareness training 
followed by more in-depth sessions involving role plays and guidance in how 
to ask about substance misuse and deal with disclosures was the approach 
advocated by the treatment provider in JCP B. Front-line staff in JCP A also 
recommended visiting the treatment provider premises to gain a better idea of 
what they do and how to best promote their services to customers. 
 
4.6.5 Being open-minded and non-judgemental 
Stakeholders acknowledged that changing attitudes within the Jobcentre in 
relation to substance misuse represents a significant culture change which will 
take time to achieve and will not happen overnight. However the treatment 
providers, DDCs and Drug Champions were keen to stress the importance of 
staff keeping an open mind about substance misusing customers, not making 
assumptions about or stereotyping them and instead learning to simply listen 
to them and advise without judging. Front-line staff in JCP A echoed the 
importance of listening carefully and responding to customers’ experiences 
and situations on a case by case basis because ‘one size doesn’t fit all’ with 
this group. Stakeholders were also keen to emphasise the importance of staff 
proactively challenging any negative attitudes that they hear being expressed 
by their colleagues to help speed up the rate of attitudinal change, and spread 
the message that this customer group needs support rather than negative 
judgement from JCP staff in order to successfully move towards employment.  
 
4.6.6 Other advice 
Other advice that stakeholders would give centred around the importance of 
having a committed and motivated Drug Champion (or Champions) in the 
office; being as flexible as possible during the trial to ensure any problems 
can be successfully overcome and the IA adapted and improved if it (or 
elements of it) are not working; having a clear referral pathway to the 
treatment provider and ensuring that all staff know how to make a referral; 
and developing close links with the staff dealing with rapid reclaims in JCP to 
target customers who display chaotic behaviour (suggesting potential 
substance misuse) and are therefore frequently sanctioned or lose their 
benefits. The treatment provider in JCP B suggested that it would be helpful if 
the NTA issued guidance on working closely with JCP. They also suggested 
that JCP outreach sessions in treatment provider premises would be more 
useful, in their view, than treatment provider sessions in the JCP. Lastly, 
some front-line staff said they would advise other staff not to feel pressured 
into asking customers about substance misuse, but instead only to broach the 
issue if and when they feel comfortable doing so. 
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 5. Quantitative Findings: Referrals and PDU markers 
 
This section contains details of the two main outcome measures focused on 
during the IA trial: the number of customer referrals to a discussion with a 
treatment provider that took place; and the number of PDU markers that were 
set on the LMS system. The latter is a proxy for the number of disclosures of 
substance misuse that were made by customers.  
 
The tables in this section containing the referral figures also contain 
information on the number of starts to a discussion with a treatment provider 
(ie. the number of customers who attended the discussion to which they were 
referred) and the number of starts to a treatment programme that resulted 
from those discussions. Please note that these figures may be undercounts of 
the actual numbers attending discussions and starting treatment, due to the 
fact that, for data protection reasons, the customer’s consent is required 
before the treatment provider can notify JCP that a customer has attended a 
discussion or started treatment. Where customers did not give their consent 
this information will not have been relayed to JCP and therefore won’t appear 
in the tables. 
 
As noted earlier in Section 2.2.2, the figures produced in relation to the 
number of disclosures taking place are similarly likely to be an undercount as 
they only includes those customers who admitted to using heroin or crack 
cocaine and agreed to JCP placing this information on their LMS record26. 
However, it is likely to give a broad indication of any increase or decrease in 
the number of disclosures being made. 
 
For comparison, figures are presented relating to the 6 months prior to the IA 
Trial, the eight weeks (or four weeks in the case of JCP C) during the trial, 
and the three months directly after the trial. In the case of JCP A, figures are 
also given for the period from the introduction of the referral process (April 
2009) to November 2009, as the treatment provider did not have a presence 
in the Jobcentre during this period but did so from that point onwards. 
 
All three Jobcentres saw an increase in the rate of referrals being made and 
PDU markers set during the trial, albeit to differing degrees. The reasons 
behind this disparity in success are explored in detail in the previous chapter. 
 
5.1 Jobcentre A 
 
Please note that JCP A did not record the type of substance that referred 
customers were misusing (ie. whether it was heroin and/or crack cocaine, 
another drug, or alcohol) and hence these figures cannot be broken down by 
these sub-groups in Table 2. 
 
                                            
26 Due to data protection, customers have to consent to having information about substance 
misuse added to their electronic record. If they do not give their consent then this information 
is not recorded. 
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 Table 2:  Referrals, starts to a discussion and starts to treatment in JCP 
A by time period in which they were made 
 
Time period1 
Referrals to a 
discussion with 
a treatment 
adviser 
Starts to a 
discussion 
with a 
treatment 
adviser (where 
known) 
Starts to 
treatment 
(where known) 
Before trial (April 09 
– end Nov 09) 0 0 0
Before trial (6 
months prior to trial 
start) 13 6 10
During trial (8 
weeks) 
6 (+2 self 
referrals)2 4 3
Post trial (3 months 
after trial) 2 1 1
1Please note that only PDUs were referred before the trial, but during and 
following the trial misusers of any substance (including alcohol) were referred.  
2 ‘Self-referrals’ refers to customers who visited the treatment provider to 
discuss treatment options after finding out about them through the Jobcentre, 
but who were not officially referred by JCP. 
 
Table 3:  PDU markers in JCP A by time period in which they were set 
 
Time period In treatment markers set 
Not in treatment 
markers set 
Total markers 
set 
Before trial (6 
months prior to trial 
start) 3 8 11 
At the end of the 
trial (8 weeks) 4 5 9 
Post trial (3 months 
after trial) 0 0 0 
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 5.2 Jobcentre B 
 
Table 4:  Referrals, starts to a discussion and starts to treatment in JCP 
B by time period in which they were made and type of referral 
 
Time period and 
type of referral 
Referrals to a 
discussion with 
a treatment 
adviser 
Starts to a 
discussion 
with a 
treatment 
adviser (where 
known) 
Starts to 
treatment 
(where known) 
Before trial (6 
months prior to 
trial start) 1 0 0
Heroin and crack 1 0 -
Other drugs 0 0 -
Alcohol 0 0 -
During trial (8 
weeks) 3 0 0
Heroin and crack 0 0 0
Other drugs 1 0 0
Alcohol 2 0 0
Post trial (3 
months after trial) 4 2 0
Heroin and crack 4 2 0
Other drugs 0 0 0
Alcohol 0 0 0
 
 
Table 5:  PDU markers in JCP B by time period in which they were set 
 
Time period In treatment 
markers set 
Not in treatment 
markers set 
Total markers 
set 
Before trial (6 
months prior to 
trial start) 5 2 7
At the end of the 
trial (8 weeks) 11 4 15
Post trial (3 
months after 
trial) 13 4 17
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 5.3 Jobcentre C 
 
Table 6:  Referrals, starts to a discussion and starts to treatment in JCP 
C by time period in which they were made and type of referral 
 
Time period and 
type of referral 
Referrals to a 
discussion with 
a treatment 
adviser 
Starts to a 
discussion 
with a 
treatment 
adviser (where 
known) 
Starts to 
treatment 
(where known) 
Before trial (6 
months prior to 
trial start) 12 3 2
Heroin and crack 4 0 0
Other drugs 2 1 1
Alcohol 6 2 1
During trial (4 
weeks) 21 12 8
Heroin and crack 8 3 2
Other drugs 4 3 1
Alcohol 9 6 5
Post trial (3 
months after trial) 55 32 1
Heroin and crack 31 18 1
Other drugs 13 5 0
Alcohol 11 9 0
 
 
Table 7:  PDU markers in JCP C by time period in which they were set 
 
Time period In treatment 
markers set 
Not in treatment 
markers set 
Total markers 
set 
Before trial (6 
months prior to trial 
start) 20 9 29
At the end of the 
trial (4 weeks) 12 5 17
Post trial (3 months 
after trial) 4 3 7
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 6. Conclusions and Recommendations 
 
This final chapter considers the main conclusions emerging from the 
evaluation, and recommendations for best practice arising from those 
conclusions for Jobcentres who wish to adopt a model of working with 
treatment providers similar to that tested in the IA trial. Additionally, it also 
includes broader best practice recommendations for implementing the 
substance misuse strategy, applicable across all Jobcentre Plus offices. 
 
6.1 Conclusions 
 
As the findings in Section 4 illustrate, stakeholder views about the trial were 
broadly positive, with general perceptions (with a few exceptions) being that it 
had been a success. The model of closer working trialled was perceived as 
having a particularly positive impact in relation to: 
 
 changing JCP staff attitudes towards substance misusers, increasing 
their understanding of the needs of this customer group, and improving 
their skills in supporting them; 
 forging good working relationships between Jobcentre Plus and the 
treatment providers, increasing understanding between the two 
organisations and knowledge of the services that the other offers; 
 raising the profile of the substance misuse agenda amongst JCP staff, 
including senior management and customer facing staff, and helping to 
embed it in everyday working practices; and 
 improving the experience of and service provided by Jobcentre Plus for 
substance misusing customers. 
 
Where the IA worked well, this model of closer working was viewed as being 
beneficial for all parties involved. For the treatment providers it was seen to 
offer an opportunity to work in a new environment and engage with individuals 
who they might not otherwise come into contact with, as well as to increase 
their knowledge of JCP services and thereby become better placed to support 
their clients in resolving any issues they may have around their benefits or 
accessing employment support. For JCP the IA was perceived as increasing 
staff skills and confidence, improving staff knowledge of the services available 
to customers with substance misuse issues, and increasing the likelihood of 
staff making a referral to a treatment provider. For the substance misusing 
customers themselves, stakeholders felt that the IA helped to remove the 
barriers that often prevent individuals from making initial contact with 
treatment providers, and also started to improve their trust in and attitudes 
towards JCP. All the treatment providers involved could cite cases where 
substance misusing customers had, as a result of the trial, been helped to 
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 access support which they needed but had not previously managed to 
access. This included benefit and employment advice from JCP, as well as 
treatment advice and support in relation to their dependency from the 
treatment provider. This sort of holistic, joined-up provision of services is a 
key element of the recovery and reintegration strand of the 2010 Drug 
Strategy27. 
 
The exception to this positive view was held by the treatment provider and 
some front-line staff in JCP B who felt that the trial had not been successful. 
This was perceived as being largely a result of the difficulties it faced in 
getting off the ground due to the negative outcome of the Health and Safety 
risk assessment, the mixed messages that JCP staff received about the trial 
from TU representatives, and the lack of buy-in from some managers. 
Although there was recognition that, following the second risk assessment 
half-way through the trial which lifted some of the restrictions on the treatment 
provider activities, the situation had improved, it was felt that the ‘damage had 
been done’ and that it was hard for the trial to recover, bed in and start seeing 
significant success after such a problematic start.  
 
There was recognition in JCPs A and B by those who deemed the trial to have 
been a success that this success was not reflected by the increase in 
numbers of referrals achieved during the trial period, which was only 
moderate in these trial sites. However, even in Jobcentre C which saw the 
largest increase, the number of referrals was still substantially smaller than 
the estimate which JCP hoped could be achieved, indicating that these 
estimates may need to be revised downwards. Stakeholders in all sites were 
keen to point out that cultural and attitudinal change within JCP and amongst 
substance misusing customers is a gradual process that takes time. They felt 
that the 4-8 weeks of the trials represented only the start of that process, and 
were hopeful that a further increase in the rate of disclosures and referrals 
would follow were the IA activities to be continued.  
 
In the case of JCPs A and C, the activity (albeit in a modified form) was 
extended past the end of the trial period, and in JCP C in particular significant 
numbers of referrals continued to be achieved during this time. The 
willingness of the treatment providers and JCP staff involved to extend the IA 
past the end of the trial despite the significant resource involved provides 
evidence of their belief in its efficacy. 
 
                                            
27 Home Office (2010) Reducing demand, restricting supply, building recovery: supporting 
people to live a drug-free life 
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 6.1.1 Evidence gaps 
To fully understand the effects of closer working between treatment providers 
and JCP in the model adopted by the IA trial, additional research would be 
valuable to explore the experiences and perceptions of substance misusing 
customers and treatment provider clients around IA. Anecdotal evidence from 
treatment providers and JCP staff working closely with substance misusers 
during the trial suggests they were positive about this closer working, that it 
had been easier for them to access the advice and support they need as a 
result of it, and that it had started to improve their views of and attitudes 
towards JCP. However, these assertions need to be validated by robust 
research with customers and treatment provider clients themselves. This work 
should explore which elements of the IA trial the customers found particularly 
positive from their perspective, and which had less of a beneficial effect.  
 
A small-scale survey of 46 treatment service users, conducted as part of this 
research in collaboration with the D(A)AT working in the area of JCP A, 
explored the issue of barriers and facilitators to the disclosure of substance 
misuse. The findings indicated that never having been asked about substance 
misuse by JCP staff, being worried about stigma, worried about how their 
benefits would be affected, and a lack of privacy in the JCP office were 
among the key reasons for not having disclosed to JCP. Conversely, they 
suggested that having greater privacy in JCP, being given assurances that the 
information about their substance misuse won’t be passed on to other 
agencies such as the police or Social Services, having greater awareness of 
the support that JCP could provide them with, and having greater flexibility in 
their benefit conditionality (for example, not having to sign on every fortnight if 
they are on Jobseekers’ Allowance) would all encourage substance misusers 
to disclose to JCP. The last suggestion, around appropriate relaxation of 
benefit conditionality, is being proposed for substance misusers in treatment 
as part of the new Drug Strategy. Further, more robust research is needed to 
verify the findings from this survey. 
 
Additional evidence would also be useful to understand which individuals are 
benefiting most from the IA. In other words, to find out whether, as a result of 
the trial, those hardest-to-reach substance misusing customers (for example, 
those experiencing the greatest number of co-occurring problems including 
mental health issues and homelessness, and those unlikely to have sought or 
accessed treatment providers otherwise) decided to take up the opportunity to 
attend a discussion with a treatment provider, or whether the customers who 
agreed to a referral would have accessed treatment provider services in the 
near future anyway, albeit possibly not as quickly or with as much ease had 
the IA trial not been in place.  Such information would help us understand 
whether more needs to be done to engage with and support those hardest-to-
reach individuals. 
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A larger scale IA trial and evaluation would be needed for a robust 
assessment of cost-benefit to be made. 
 
6.2 Recommendations 
 
6.2.1 Extending IA to other Jobcentres 
 
The IA trial has demonstrated that such a model of working can be 
successful, add value for JCP, the treatment provider and substance 
misusers, and have a positive impact on the number of disclosures and 
referrals being achieved. However, given the limited increase in referrals 
achieved during the trial and its resource intensive nature, it is unlikely that in 
the current climate many JCP offices will be able to justify adopting intensive 
activity on this scale with a view to increasing the volumes of such referrals. 
 
Any decision to adopt a form of Intensive Activity within a Jobcentre office 
must be made at the local and district level, in collaboration with the D(A)AT 
and the treatment provider(s) who would be involved. When making this 
decision consideration should be given to: 
 
 the current capacity of the DDC (or the individual who has 
responsibility for the main functions of this role post-March 2011), any 
Drug Champions who might be required to undertake caseloading or 
outreach activities, and the treatment provider(s) who would be 
involved; 
  the current level of disclosures and referrals being achieved by the 
Jobcentre in comparison to the estimated scale of the substance 
misuse problem (and level of treatment penetration) in the office 
catchment area; and 
 the expert knowledge of the local treatment provider(s) in relation to 
whether the substance misusers in the area would benefit from such 
activity. 
 
For those Jobcentres who take the decision to introduce the IA model in their 
office, the trial has provided various lessons for best practice which are 
discussed in Section 6.2.2 below. The trial has also highlighted broader 
lessons for best practice when supporting substance misusing customers 
which are of relevance to all Jobcentres, regardless of whether or not they 
decide to introduce a treatment provider presence into their office. These 
recommendations are detailed in Section 6.2.3. 
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 The lessons for best practice contained within this report do not constitute an 
exhaustive list of the most effective ways for JCP to work with treatment 
providers to provide a more holistic service for substance misusing 
customers, and to increase the number of disclosures and referrals being 
made. Other innovative ways of working which have been adopted within JCP 
districts and have seen successful outcomes include the introduction of office-
level targets around referrals to a treatment provider, the use of office and 
region-level performance league tables, close working with the police, prisons 
and DIPs (Drug Intervention Programmes), and intensive previewing of 
customers’ LMS records to identify those who have a previous history of 
substance misuse recorded on the system to enable targeted offers of support 
to be made. Unfortunately, activity such as this which did not occur in the 
three IA trial sites is outside the scope of this evaluation. Further research 
would be required to compare the effectiveness and value for money of these 
approaches with the IA model. 
 
6.2.2 Lessons for best practice when developing an IA initiative 
 
For those regions or Jobcentres where it is agreed that there is sufficient need 
and capacity to support the adoption of Intensive Activity, various best 
practice lessons can be learnt from the trial to help maximise the chances of 
the activity having a significant positive effect. 
 
Treatment Provider Role 
As discussed above, any decision to introduce IA into a JCP office should be 
made in conjunction with the local D(A)AT and treatment provider to ensure 
they have the capacity to take on such a project, and if so to establish how 
much resource they could offer. The treatment provider should be involved in 
the design of the activity to ensure that their expertise in engaging with the 
substance using population in the area is fully utilised. Additionally, as with 
Jobcentre Plus, treatment providers frequently have targets set on their 
activity by the commissioning D(A)AT (for example – in the case of the 
treatment provider in JCP C – to work predominantly with users of Class A 
drugs). Where this is the case a consideration at the development phase of 
how these might be impacted by and accommodated within the IA is essential 
if it is going to be sustainable in the longer term. 
 
The commitment of the treatment provider appears integral to the success of 
IA, so it is important that they are on-board with the goals of the initiative and 
willing to work flexibly with JCP if faced with any barriers or obstacles during 
the course of the activity. It appears beneficial if the provider has prior 
experience of conducting outreach and adapting to working in different (and 
more formal and structured) environments to that of treatment services, as 
Jobcentres represent a very different environment to those in which most 
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 treatment providers usually operate. A proactive approach on the part of the 
treatment provider – as far as possible within any restrictions imposed on their 
activity – in relation to familiarising themselves with JCP practice and 
processes, raising awareness of their presence and services and forging good 
relationships with JCP staff and customers, is likely to increase the chances of 
success of the IA. 
 
This evaluation cannot provide evidence on the optimum amount of time per 
week that treatment providers should spend in the Jobcentre as part of the IA. 
This should be agreed based on provider and JCP staff capacity and on 
perceived need. The trial has demonstrated the importance of the activity 
having a positive start and being well promoted to both staff and customers, 
and based on this we would recommend that the treatment provider commit a 
greater amount of time to the activity during the first 3-4 weeks of the trial and 
attend the office for several pre-agreed sessions per week. Following this 
more intensive period it would be sensible for the key stakeholders in the IA to 
review the situation and take a decision on whether to continue with the same 
level of attendance, increase the number of sessions, or scale back the 
amount of time they spend there.  
 
If the latter, the treatment provider might want to only attend if they have 
booked appointments with customers, or specific meetings or training 
sessions with JCP staff, if this is deemed to be the best use of their time. If the 
treatment provider has the flexibility (and is within a sufficient proximity) to 
consider attending the Jobcentre to see customers as soon as they’ve been 
referred then the evidence from JCP C suggests that this can work very well. 
The treatment provider should also consider attending the JCP on different 
days of the week if possible so as to maximise their availability to JSA 
customers on different signing cycles. Whilst it would be ideal and the best 
use of their time if treatment providers are able to approach customers to 
discuss their services, evidence from JCP C has shown that this is not a 
necessary condition for successful IA, and that even if risk assessments 
prevent this being done IA can still work well provided the treatment provider 
is sufficiently proactive in making their presence known. Having use of a 
private room, however, is essential so that customers can talk confidentially to 
providers about sensitive matters without fear of being overheard. 
 
During the first few weeks of any treatment provider presence, the evidence 
suggests an initial familiarisation period of a week or so during which the 
treatment provider focuses on better understanding the work of, and the 
procedures and processes that operate in, JCP is beneficial. This could be 
done by enabling the treatment provider to join team meetings and spotlight 
sessions, sit in on customer interviews and generally gain as much exposure 
to JCP staff and their work as is possible and appropriate. The treatment 
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 provider should also take this time to explain the work that they do and 
services they offer, and to answer any questions that JCP staff may have. 
 
Jobcentre Plus Role 
The trial suggests that Intensive Activity is most successful in Jobcentres 
where there is buy-in and commitment to the activity from management, and 
where those managers are consequently willing to give their teams the 
support and encouragement necessary to ensure that they fully engage with 
the initiative. Evidence from JCP B suggests that some team leaders did not 
adopt the activity within their teams and were not challenged on this by their 
managers. Management support is especially important to the success of IA 
as the findings from this evaluation, as well as those from a survey of advisers 
conducted by JCP Work Psychologists (unpublished internal report), have 
demonstrated that not all front-line JCP staff are confident about working with 
substance misusers, or motivated to do so. A visible show of commitment and 
encouragement from senior staff is therefore crucial in helping to change their 
attitudes to working with this customer group, and also in reinforcing the 
importance of the substance misuse strategy on what is a very crowded and 
process-driven agenda for front-line JCP staff. 
 
The evidence suggests that a significant amount of commitment is required 
from the DDC if the chances of success of an IA initiative are to be 
maximised. As a result it is recommended that, during the initial bedding-in 
phase of around 2-3 weeks, the DDC spend the majority of their time at that 
office if at all possible to promote and raise awareness of the activity amongst 
staff, ensure that the treatment provider’s time is being utilised as effectively 
as possible, and identify and help to resolve any problems early on. This will 
necessarily mean that, if the decision is taken to introduce IA into more than 
one Jobcentre falling with any one DDCs remit, it will have to be rolled out 
gradually in one office at a time. It is also likely that, even after the initial 
bedding-in period, additional DDC attention and resource will be required by 
those offices in which the IA initiative is taking place if any early success is to 
be maintained and built upon. For example, the DDC is likely to need to help 
maintain the activity’s momentum and profile within the office, regularly review 
whether any changes need to be made, and help implement them when they 
are required. Careful consideration should therefore be given to the feasibility 
of any proposals to bring IA in to more than one office within any one DDC’s 
remit. Such consideration is particularly important due to the fact that that the 
DDC role came to an end in March 2011 and Jobcentre Plus Districts now 
have the flexibility to decide how best to deliver the key functions of this role in 
light of their local priorities and resource. It therefore may not be possible for 
the member of Jobcentre Plus staff taking over these functions to devote a 
significant amount of time to such an IA initiative. 
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 The role of the Drug Champion has also been shown to be very important in 
supporting IA and maximising its success. Therefore, in offices which don’t 
currently have a Drug Champion one (or more) should be appointed prior to 
the start of the initiative. Their resource is especially important if caseloading 
or outreach by a dedicated adviser is being considered as part of the IA. 
These two elements, along with the personal qualities required by the Drug 
Champion role, are discussed further in Section 6.2.3 below. 
 
Trade Union Engagement 
As discussed earlier, the outcome of the Health and Safety risk assessment in 
JCPs B and C resulted in proposed elements of the trial not going ahead. 
These included staff visits to the treatment provider, and aspects of treatment 
provider activity during their sessions in the JCP. According to some of the 
key stakeholders, including the treatment provider, this had a significant 
impact on the success of the trial in JCP B. Before any other Jobcentres 
adopt IA it is recommended that DWP and JCP discuss the activity with the 
TU at a national level and secure agreement in principle from them to support 
and facilitate the initiative. Having the TU issue guidance for local 
representatives on completing risks assessments in relation to this activity 
would be beneficial, as would engaging local TU representatives early on in 
the development of the activity to allow sufficient time for any concerns to be 
fully discussed and solutions or compromises found. 
 
Communication 
The evaluation has highlighted the importance of good communication to all 
JCP staff about the IA and treatment provider presence, especially at the start 
of any activity. However, it has also highlighted that this is a challenge given 
the current lack of all staff meetings that appears to be a common theme 
across JCP offices. Spotlight sessions, along with any other larger staff 
meetings, as well as smaller team ones, therefore present an important 
platform for DDCs, Drug Champions and treatment providers to raise 
awareness of the provider presence and introduce them to staff. Less formal 
contact between staff and providers during the day is also important for 
building close working relationships, for example ad hoc conversations taking 
place in between Adviser appointments and in the staff area during breaks. 
The times and days that the provider will be attending the JCP, as well as 
their location whilst in the office, should be clearly communicated to staff so 
that they can refer customers immediately when they are present and 
successfully book an advance appointment when they are not. 
 
Good communication between JCP and the treatment provider is also 
important so that any problems or issues can be identified and rectified as 
soon as they arise, before they have a chance to cause any damage to 
working relationships. Following the more intensive bedding in period, a 
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 weekly or fortnightly meeting between the DDC and treatment provider would 
be one way to ensure that effective lines of communication around the IA are 
maintained. 
 
Flexibility 
As touched on earlier, flexibility on the part of both JCP and the treatment 
provider is important when implementing IA. The activity should be monitored 
closely for any emerging problems and to identify any elements that aren’t 
working well or contributing much to the success of the programme, and 
stakeholders should be prepared to formulate and implement a quick 
response, whether it be adapting these elements so that they are more 
effective, or stopping them altogether.  
 
Ultimately there are no guarantees that IA will be successful in a particular 
JCP. Therefore if, despite following the best practice recommendations and 
giving the activity sufficient time to bed in, it is not deemed to be delivering 
sufficiently positive outcomes, DDCs and treatment providers should be 
prepared to take the decision to end this model of closer working in that 
particular office and focus on developing a different approach to the 
substance misuse agenda in that office. It is crucial that stretched treatment 
provider and JCP staff resource should not be wasted if the initiative isn’t 
achieving the desired outcomes. Key stakeholders may want to consider 
setting a target around the increase in disclosures and referrals that would 
need to be achieved (following a sufficient bedding in period) for the activity to 
be considered worthwhile, based on a locally produced cost-benefit 
calculation. However, if this approach is taken it should be remembered that 
many of the benefits of closer working with treatment providers aren’t as 
easily quantifiable as disclosures and referrals, and that some ‘softer’ 
measures of success, such as whether a more holistic service is delivered to 
substance misusing customers, may be just as important in the longer term.  
 
6.2.3 General lessons for best practice in JCP 
 
Even in JCP offices where the decision is taken not to adopt Intensive Activity, 
various best practice lessons emerging from the IA trial can be implemented 
which should help to improve the service for substance misusing customers. 
 
Drug Champion role 
Drug champions have been shown to add significant value by assisting the 
DDC in embedding the drug strategy on the JCP agenda; providing support 
and advice to colleagues on how to ask customers about substance misuse, 
deal with disclosures and make referrals; and working with the DDC to identify 
and develop solutions to any problems in relation to the strategy in the office. 
Additionally, the trial in JCPs A and C demonstrated that Drug Champions can 
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 successfully undertake outreach in treatment provider premises and 
caseloading of substance misusing customers (both of which are considered 
in more detail below).  
 
JCPs A and B both had one Drug Champion, but JCP C had five: one 
Champion per team. Whilst there is some evidence to suggest this latter 
model worked well to ensure that the profile of the substance misuse strategy 
was raised in each team and that each had a resource on hand when help 
and advice was needed, the evaluation suggests that the most important 
factor is that the Drug Champion(s) have the necessary excellent inter-
personal skills, passion and enthusiasm to work with what can be a 
challenging customer group. Anecdotal evidence from DDCs suggests that if 
the Champion is not committed to the agenda or is not comfortable working 
with substance misusing customers it can be difficult to keep them engaged in 
the role, and it is therefore likely that their impact will be limited.  
 
The capacity of any staff members who want to become Drug Champions 
needs to be considered carefully before they are given the role. Consideration 
should also be given to tailoring their productivity targets to take into account 
of any work they will be doing with substance misusing customers as part of 
this role, this being a customer group amongst whom outcomes such as 
training and employment starts are far more difficult to achieve when 
compared to the ‘average’ JCP customer. Evidence from the trial evaluation 
suggests that if Drug Champions are expected to work more intensively with 
substance misusing customers but still achieve the standard productivity 
targets then their role may not be sustainable in the longer term. 
 
Outreach 
The experience in JCP A demonstrated that outreach conducted by an 
Adviser (possibly the office’s Drug Champion) experienced in working with 
substance misusers can be successful in helping to engage such customers 
in conversations about benefits and work who might not be engaging with 
these issues in a meaningful way when they visit JCP, and starting to move 
them towards their employment goals. Such an approach could become even 
more important once tailored conditionality is implemented, and customers in 
treatment are no longer required to visit the Jobcentre on a regular basis due 
to the relaxation of conditionality around their benefits. The Drug Strategy 
contains a commitment that JCP will ‘work in close partnership with drug and 
alcohol services, and will offer face-to-face support, advice and guidance on 
benefits and employment, through outreach where appropriate, to service 
users and the drug and alcohol professionals who support them’28.  
                                            
28 Home Office (2010) Reducing demand, restricting supply, building recovery: supporting 
people to live a drug-free life, page 21. 
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As with the Drug Champion role, empathy and compassion are very important 
personal qualities for an Adviser conducting outreach with substance 
misusers, as are being non-judgemental and a good listener. Again, 
consideration would need to be given as to how to overcome the conflict 
between this work and Adviser productivity targets, as such outreach sessions 
are likely to be more time consuming but result in less training and 
employment outcomes due to the nature of this customer group and their 
likelihood of being a greater distance from the labour market. In terms of 
necessary equipment, providing the Adviser with a 3G card and laptop so that 
they can access and update LMS records during the outreach sessions would 
help to maximise the value that can be gained from them.  
 
In relation to Health and Safety risk assessments for outreach in treatment 
provider premises, evidence from JCP A suggests that it is beneficial if the 
treatment provider manager, along with the member of JCP staff who will be 
conducting the outreach, is present at the time of the assessment. The 
evaluation also suggests it is beneficial if the provider is able to be flexible in 
response to any problems or obstacles raised by the assessment and find 
solutions or compromises to them. 
 
Caseloading 
As with outreach, evidence from JCP C suggests that the caseloading of 
substance misusing customers to an Adviser experienced in working with this 
group this can be a successful way of facilitating the development of more 
positive working relationships between JCP and these customers. Customers 
with such issues often require more intensive and time-consuming support 
from their Adviser in order to start to progress towards the labour market, and 
someone with a dedicated remit to work with this group (if only for a portion of 
their time) may be best placed to provide this. The personal qualities and 
skills mentioned in the previous section (empathy, compassion, having a non-
judgemental attitude and being a good listener) are all just as relevant here, 
as is the necessity of overcoming the conflict between this work and 
productivity targets if such activity is to be sustainable over the longer term. 
 
Close working relationships between treatment providers and JCP 
The IA trial has demonstrated that close working relationships between 
treatment providers and JCP can improve the service that substance 
misusers receive from both organisations. The IA trialled a particular model of 
closer working, however the relationship between JCP and local treatment 
provider(s) can be developed and strengthened in less resource intensive 
ways. For example, having the treatment provider attend the JCP for a 
‘familiarisation week’ similar to that recommended at the beginning of an IA 
trial during which they can attend team meetings, observe customer 
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 interviews and speak to JCP staff about their roles could help the provider to 
gain greater insight into the work of JCP and the support on offer to substance 
misusing customers. It could also provide them with the opportunity to 
suggest improvements that could be made to JCP’s service that would benefit 
substance misusers. In exchange, a visit to the treatment provider for key JCP 
staff and a presentation for the rest of the office on the services they provide 
would help to inform and raise awareness amongst JCP about their work, and 
hopefully increase the likelihood of staff recommending a referral to them to 
appropriate customers. 
 
Training 
The evaluation has demonstrated the importance of JCP staff attending 
training to increase their motivation and confidence in working with substance 
misusing customers. The evidence suggests that awareness sessions are not 
sufficient to achieve this, and instead that Advisers and other staff benefit 
most from training that gives them the tools to raise the question of substance 
misuse with customers and respond sensitively and effectively to customer 
disclosures, as well as an understanding of the limitations that different forms 
of treatment (such as substitute prescribing) place on customers’ capability for 
work. The IA evaluation suggests that having treatment providers delivering 
the training is a good way of making use of their expertise in working with 
substance misusers, but in other offices not included in the trial JCP Work 
Psychologists have also delivered successful training. The use of role plays 
and techniques such as Neuro-Linguistic Programming (NLP)29 have 
anecdotally achieved good results. Although getting JCP staff released to 
undertake such training is difficult at the current time, it is important that all 
front-line staff receive it given JCP’s commitment under the Advisory Services 
of the Future (ASoftF) initiative to ensure that all Advisors have the necessary 
skills to work with customers with any barriers, including substance misuse. 
 
Other positive processes and activities 
The evaluation suggests that case conferencing, previewing LMS records for 
signs of prior drug misuse, referral process ‘walk-throughs’, and having a 
private room available in which to discuss substance misuse with customers 
are all helpful for this group. Further details about these activities can be 
found in Section 4.2.8. 
 
                                            
29 NLP has been defined as an approach to psychotherapy and organisational change based 
on ‘a model of interpersonal communication chiefly concerned with the relationship between 
successful patterns of behaviour and the subjective experiences (especially patterns of 
thought) underlying them’ (Bandler and Grinder, 1979). Originally developed as a form of 
psychological therapy, it was later promoted as a means by which people can improve their 
effectiveness by ‘modelling’ themselves on successful individuals in their field. 
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 Whether or not IA is adopted in a particular JCP office, the sharing of 
experiences, developments and best practice between offices and between 
treatment providers is crucial for ensuring that stakeholders learn from each 
other and build on each other’s knowledge. Alongside utilising current 
platforms for the sharing of best practice it might be valuable to set up some 
new ones involving treatment providers and D(A)ATs as well as JCP staff. 
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 Appendix A – Stakeholder & front-line JCP staff discussion topic guide 
 
Topic Guide – stakeholders and front-line JCP staff 
 
1. Could you go around the table and tell me briefly what your role was in the 
trial, and what impact it had (if any) on your daily work routine? 
 
2. Could you give me a brief description from someone of all the activities that 
were carried out or changes that were made as part of the trial here? And the 
number of referrals, starts and PDU/other drug or alcohol markers that were 
made or set during this period? 
 
3. What were your initial thoughts and feelings when you heard about this trial 
and what it was going to involve?  
 
Probe: -    Worried about extra workload/responsibility 
- Worried about customer reaction 
- Pleased that it would involve extra training and development 
of your role 
- Positive about the opportunities it would bring to develop the 
service you offer customers 
- Scepticism about the aims of the trial 
 
4. Did they change over the course of the trial? 
 
5. Overall, do you think the trial has been a success? Why or why not? What 
do you think its impact has been? 
 
Probe: -    On you in particular (more or less work) 
- On (other) staff and customers (reactions) 
- Do you have more insight into the customers/drug users 
- Has it helped you better able to identify substance 
misusers/raise this issue with customers 
- Has it been more successful with PDUs than with other drug 
or alcohol misusers, or vice versa 
 
6. What elements of the trial did you feel worked particularly well? Why do you 
think they worked so well, and what were their effects? 
 
7. What elements did you feel worked less well and why? Could these 
elements have been improved by making some changes to how they were 
implemented or what they involved? If so what changes? 
 
Probe any elements not mentioned at the last two questions: 
 
- Marker trial (JCP A only) 
- Treatment provider presence in JCP 
- Training for staff/visits to treatment providers 
- ‘Do you need help’/ ‘Are you missing out?’ forms 
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 - JCP outreach sessions in treatment provider premises (JCP 
A only) 
 
8. What problems did you encounter during the trial? Could these have been 
overcome by doing things slightly differently, and if so how? 
  
Probe:  -    TU resistance 
- Resistance from personal advisers or other JCP staff 
- Hostility or negative feedback from customers 
- Procedural or logistical problems (eg. lack of desks for 
treatment providers, lack of privacy when talking to 
customers etc) 
- Workload pressues 
 
9. What would you have done differently during the trial if you had known what 
you know now? 
 
10. Are there any additional changes/interventions you think would have been 
effective as part of the trial but weren’t included? 
 
Probe: -    JCP outreach sessions at treatment providers (JCP B and C   
                           only) or other locations where substance misusers are likely  
                           to be 
- Having a specialist adviser for substance misuse issues (as 
with disability issues) 
 
11. Are you planning on carrying on with the Intensive Activity after the trial 
period? If not at all/if not any particular elements, why not? For all substance 
misusers or focusing on PDUs? 
 
12. Do you see the Activity as sustainable over the long term? If not why not? 
Did it place an undue burden on you/colleagues/staff in terms of time, 
paperwork or responsibility? 
 
13. Do you think it’s realistic to roll this Activity out nationally? Why/why not? 
Are there any particular circumstances that mean the outcome of the trial is 
quite specific to your area? 
 
14. What are the three key tips or pieces of advice you would give to other 
JCP areas who are just about to introduce Intensive Activity?  
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 Appendix B – Treatment provider discussion topic guide 
 
Topic Guide – treatment providers 
 
1. Please could you start by telling me your name, role in [treatment provider] 
and what your day-to-day job involves? 
 
2. Could you also tell me about what you and your colleagues did as part of 
the Intensive Activity trial? 
 
Probe: -    Presence at the JCP office 
- Familiarisation days 
- Training for JCP staff 
 
3. What were your initial thoughts and feelings when you heard about this 
trial and what it was going to involve? 
 
Probe: -    Worried about extra workload/responsibility 
- Scepticism about the aims of the trial/working with JCP 
- Positive about the new opportunities it would bring to 
develop the service you offer substance misusers 
 
4. Did these views change over the course of the trial? 
 
5. Overall, do you think the trial has been a success? Why or why not? What 
do you think its impact has been? 
 
Probe: -    On you in particular (more or less work) 
- On colleagues, JCP staff and substance misusing 
customers/clients  
- Do you have more insight into the customers/drug users 
- Has it helped you better able to identify substance 
misusers/raise this issue with customers 
- Has it been more successful with PDUs than with other drug 
or alcohol misusers, or vice versa 
 
6. Did taking part in the trial have any positive or negative impacts on your 
everyday work at [treatment provider]?  
 
7. What elements of the trial did you feel worked particularly well? Why do 
you think they worked so well, and what were their effects? 
 
8. What elements did you feel worked less well and why? Could these 
elements have been improved by making some changes to how they were 
implemented or what they involved? If so what changes? 
 
Probe any elements not mentioned at the last two questions: 
 
- Marker trial (JCP A only) 
- Treatment provider presence in JCP 
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 - Training for staff/visits to treatment providers 
- ‘Do you need help’/ ‘Are you missing out?’ forms 
- JCP outreach sessions in treatment provider premises (JCP 
A only) 
 
9. What problems did you encounter during the trial? Could these have been 
overcome by doing things slightly differently, and if so how? 
  
Probe:  -    TU resistance 
- Resistance from personal advisers or other JCP staff 
- Hostility or negative feedback from customers 
- Procedural or logistical problems (eg. lack of desks for 
treatment providers, lack of privacy when talking to 
customers etc) 
- Workload pressures 
 
9. What would you have done differently during the trial if you had known 
what you know now? 
 
10. Are there any additional changes/interventions you think would have been 
effective as part of the trial but weren’t included? 
 
Probe: -    JCP outreach sessions at treatment providers (JCP B and C   
                           only) or other locations where substance misusers are likely  
                           to be 
- Having a specialist adviser for substance misuse issues in 
the JCP office 
 
11. Are you planning on carrying on with the Intensive Activity after the trial 
period? If not at all/if not any particular elements, why not? For all 
substance misusers or focusing on PDUs? 
 
12. Do you see the Activity as sustainable over the long term? If not why not? 
Did it place an undue burden on you/colleagues/staff in terms of time, 
paperwork or responsibility? 
 
13. Do you think it would be feasible for other treatment providers to adopt a 
similar way or working with JCP as you have been doing as part of the 
trial? Is there anything unique about your organisation that made you 
particularly well placed (or not well placed) to do it? 
 
14. What are the three key tips or pieces of advice you would give to other 
treatment providers who are about to take part in an Intensive Activity 
initiative?  
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 10. Appendix C – ‘Are you missing out?’ form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARE YOU MISSING OUT? YES  NO N/A
1. Do you have a disability/health condition that is affecting you looking     
for work?      
    
2. Is your first language anything other than English?      
    
3. Do you have difficulty reading, writing or maths?      
    
4. Do you hold qualifications below NVQ Level 2 (5 GCSE’s)?      
    
5. Do you have any Children/Dependants?      
    
6. Are you bringing up children on your own?      
     
7. Are you homeless?      
     
8. Have you at any time completed a custodial sentence?      
     
9. Are you concerned about your own drugs /alcohol use?      
     
10. Are you getting any structured support for your drug /alcohol use?      
     
11. Are you now abstinent from drugs?      
     
12. Are you looking for training opportunities?      
Customers have told us that they don’t always know about all the 
help currently available. 
Please take some time to look through this list.  If any of the 
following applies to you, please tick the appropriate box 
Are You Missing Out? 
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 Appendix D – JCP C Q&A sheet for Personal Advisers 
 
Possible Questions asked by Service Users 
 
This is a log of questions that may be asked by Service Users. It will 
help key workers in eliminating some of their concerns whilst 
encouraging them to declare their drugs use to Jobcentre Plus. 
  
If users disclose their drug use Jobcentre Staff will be able to direct them to 
specific programmes and additional support. 
 
 
1. Q - If I declare to Jobcentre Plus that I am a Problem Drug User, will 
my benefit be affected? 
 
A – No, your benefit will not be affected.  It is in your interest to declare 
because Jobcentre Plus advisers will be able to support you and 
arrange an appointment for a discussion with your local treatment 
provider. 
 
2. Q – Will Jobcentre Plus staff tell the Police and Social Services that I 
am a Problem Drug User? 
 
A – No, Jobcentre Plus takes security matters very seriously.  All 
information is treated in strict confidence in accordance with the data 
protection act. Information will not be disclosed unless JCP are ordered 
by a court or have lawful authority.  
 
3. Q – If I am already in treatment with a drug service, will Jobcentre Plus 
staff force me to take part in Jobcentre Plus programmes? 
 
A – There are certain programmes within Jobcentre Plus that are 
mandatory and therefore you will have to take part in.  However, 
Jobcentre Plus staff will endeavour to be flexible to ensure that the 
steps you are taking to get you back into work do not affect your 
recovery plan.  This is why it’s important that you tell Jobcentre Plus 
that you are in Treatment.  
 
4. Q – I am worried that other people can hear my conversation during my 
interview; can I talk to my adviser in private? 
 
A – Yes, a private interview room can be requested 
 
5. Q - What if there is not enough time during my interviews to discuss my 
drug issues? 
 
A – You can request another interview with your adviser to discuss 
specific areas of concern. 
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 6. Q - Will Jobcentre Plus pay my travel costs to attend an initial 
discussion with a Treatment Provider? 
 
A – Yes, you will need to bring your bus ticket/s. For those travelling by 
car can claim mileage expenses. 
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 Appendix E – JCP C drugs quiz 
 
Drugs Quiz 
 
1. Are you aware of the JCP drugs Strategy? 
 
 
2. What is the telephone number to refer a customer for a discussion with 
a treatment provider? (SPOC) 
 
 
3. Which form needs to be completed to gain customer consent? 
 
 
4. Why is it important to set disadvantaged markers? 
 
 
 
5. For Which customers would you set the In Treatment/Not In Treatment 
Pilot marker? 
 
 
6. Which form is required when referring a Problem Drug User for a 
voluntary discussion with a Treatment Provider?  
 
 
7. Name the 5 Drug Champions at this JCP 
 
 
 
8. Which Treatment Provider has a presence in this Jobcentre? 
 
 
 
9. What sort of help is available from Drug Treatment Providers (list as 
many as possible) 
 
 
 
10.  Who is the ASM Drugs Lead in this JCP? 
 
 
11. Name the Drugs Co-ordinator linked to this JCP?  
           
 
12.  Have you heard of the Adviser Drug Box? 
 
Name:      
 
(There will be a small prize for the person/s with the most correct answers). 
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 Please pass the completed forms to your team drug champion, DDC or 
treatment provider. 
 
Many thanks  
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  Appendix F – JCP C referral process memory aide  
 
Voluntary Referral to [treatment provider]: tel xxxxxx   
 
If customer wishes to be seen by different provider or not in office, 
follow SPOC process and phone xxxxxx for an appointment. 
 
Customer identified as  
Drug/Alcohol User 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phone [treatment provider or 
use appointment sheet (held 
by Lead Drug Champion) 
Print & issue LMS letter  
(amend appropriately) 
Complete TPR1 form and place in 
folder held by Lead Drug Champion
TPR1
If customer 
not willing to 
sign DPA1 
signpost to 
[treatment 
provider] 
No action is 
taken if 
customer 
declines 
appointment 
with [treatment 
provider] 
If not already in Treatment 
encourage customer to attend 
informal discussion with [treatment 
provider] during their sessions in 
the office. Consider referring to 
other appropriate JCP provision 
Chaotic users to 
[alternative 
provision]  
 
Non chaotic 
users to 
progress2work 
Adobe Acrobat 7.0 
Document  
       Complete DPA1 form If customer 
refuses to sign 
DPA1 the 
LMS markers 
should NOT 
be set 
 
‘In Treatment’ or ‘Not in 
Treatment’ pilot markers 
should be set on LMS for 
customers using crack 
cocaine and/or heroin & 
claiming JSA/ESA 
Set LMS marker and submit 
customer to LMS opportunity   
depending on drugs or alcohol 
ERG/7949 (Crack/Heroin) 
ERG/8700 (Other Drugs) 
ERG/8699 (Alcohol) 
ERG/8777 (Heroin/Crack Users on 
IB/IS Only) 
Checklist – Have you: 
-Set Disadvantaged Marker (if 
DPA1 signed)? 
-Set Not/In Treatment 
Markers?(crack & heroin 
ONLY) 
-Completed TPR1 form  
-Arranged Follow Up?
Record all conversation 
details in ACTION PLAN 
including drug of choice. 
Note More Box ‘DPA1 & TPR1 
completed + which drug 
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Issue customer the details of 
appointment from LMS Arrange 
follow up 
IF CUSTOMER ALREADY IN TREATMENT, ASK WHICH 
PROVIDER/KEY WORKER. SET THE PILOT MARKER TO 
“IN TREATMENT”
  
This report presents the findings of an evaluation of a small-scale Jobcentre Plus trial aimed 
at customers with drug and alcohol addiction. 
The Intensive Activity trial took place in three Jobcentres between May and July 2010 and 
offered an enhanced service to claimants with dependency issues, including the regular 
presence of a treatment provider in the Jobcentres.  The trial was designed to help improve 
the service delivered to substance misusing customers, to further develop partnership 
working between treatment providers and Jobcentres, and to increase the level of voluntarily 
referrals made by Jobcentre Plus to a treatment provider. 
The evaluation, carried out by social researchers at the Department for Work and Pensions, 
involved qualitative research with key stakeholders and the monitoring of Management 
Information. 
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